| Fertility and Sterility | 87.5 | 2 | 3 |
| Prelude Fertility | 80.0 | 3 | 1 |
| Pacific Fertility Center Los Angeles (PFCLA) | 80.0 | 3 | 1 |
| Colorado Center for Reproductive Medicine | 67.5 | 2 | 1 |
| National Institute for Occupational Safety and Health | 60.0 | 3 | 0 |
| Parents | 60.0 | 3 | 0 |
| Vital and health statistics. Series 21, Data on natality, marriage, and divorce | 60.0 | 3 | 0 |
| Vital and health statistics. Series 5, Comparative international vital and health statistics reports | 60.0 | 3 | 0 |
| Pacific Fertility Center | 60.0 | 3 | 0 |
| Office of Readiness and Response | 60.0 | 3 | 0 |
| American Society for Reproductive Medicine | 50.0 | 1 | 1 |
| Epi Info | 47.5 | 2 | 0 |
| Europe This Week | 47.5 | 2 | 0 |
| Live Science | 47.5 | 2 | 0 |
| Market Watch | 47.5 | 2 | 0 |
| Preventing Chronic Disease | 47.5 | 2 | 0 |
| National Survey of Family Growth | 47.5 | 2 | 0 |
| The Profit | 47.5 | 2 | 0 |
| National Vital Statistics System | 47.5 | 2 | 0 |
| NIOSH Power Tools Database | 47.5 | 2 | 0 |
| Morbidity and Mortality Weekly Report: Recommendations and Reports | 47.5 | 2 | 0 |
| Vital & health statistics. Series 3, Analytical and epidemiological studies | 47.5 | 2 | 0 |
| Vital and health statistics. Series 3, Analytical studies | 47.5 | 2 | 0 |
| Vital and health statistics. Ser. 4, Documents and committee reports | 47.5 | 2 | 0 |
| Vital and health statistics. Series 13, Data from the National Health Survey | 47.5 | 2 | 0 |
| Aging trends (Hyattsville, Md.) | 47.5 | 2 | 0 |
| NCHS data brief | 47.5 | 2 | 0 |
| MMWR supplements | 47.5 | 2 | 0 |
| National Center for Emerging and Zoonotic Infectious Diseases | 47.5 | 2 | 0 |
| Division of Parasitic Diseases and Malaria | 47.5 | 2 | 0 |
| Chronic Disease Prevention and Health Promotion | 47.5 | 2 | 0 |
| Fertility Center of Las Vegas | 47.5 | 2 | 0 |
| Shady Grove Fertility Center | 47.5 | 2 | 0 |
| Fertility Centers of Illinois | 47.5 | 2 | 0 |
| New Hope Fertility Center | 47.5 | 2 | 0 |
| West Coast Fertility Centers | 47.5 | 2 | 0 |
| Back in the Game | 47.5 | 2 | 0 |
| University of Pennsylvania Division of Endocrinology, Diabetes and Metabolism | 47.5 | 2 | 0 |
| Healthcare Infection Control Practices Advisory Committee | 47.5 | 2 | 0 |
| Progyny, Inc. | 47.5 | 2 | 0 |
| assisted reproductive technology | 40.0 | 0 | 3 |
| fertility clinic | 40.0 | 0 | 3 |
| Money Management International | 40.0 | 0 | 3 |
| Predictors of pregnancy and live-birth in couples with unexplained infertility after ovarian stimulation-intrauterine insemination | 40.0 | 0 | 3 |
| Couples with unexplained subfertility and unfavorable prognosis: a randomized pilot trial comparing the effectiveness of in vitro fertilization with elective single embryo transfer versus intrauterine insemination with controlled ovarian stimulation | 40.0 | 0 | 3 |
| Association of uterine fibroids and pregnancy outcomes after ovarian stimulation-intrauterine insemination for unexplained infertility. | 40.0 | 0 | 3 |
| Risk-sharing or refund programs in assisted reproduction: a committee opinion | 40.0 | 0 | 3 |
| Financial "risk-sharing" or refund programs in assisted reproduction: an Ethics Committee opinion | 40.0 | 0 | 3 |
| Single embryo implantation per IVF cycle: the answer to every request for assisted reproduction? | 40.0 | 0 | 3 |
| Shared-risk or refund programs in assisted reproduction. The Ethics Committee of the American Society for Reproductive Medicine | 40.0 | 0 | 3 |
| Effect of Addition of Aromatase Inhibitor to Ovarian Stimulation Therapy in IVF Treatment | 40.0 | 0 | 3 |
| Shared-risk or refund programs in assisted reproduction | 40.0 | 0 | 3 |
| GYN-FIV a.s. | 40.0 | 0 | 3 |
| money back guarantee | 31.7 | 0 | 2 |
| GoodLeap | 31.7 | 0 | 2 |
| health expenditure | 31.7 | 0 | 2 |
| Journal of Assisted Reproduction and Genetics | 31.7 | 0 | 2 |
| Financial Counseling and Planning | 31.7 | 0 | 2 |
| Reproductive Medicine and Biology | 31.7 | 0 | 2 |
| Post-embryo transfer interventions for assisted reproduction technology cycles | 31.7 | 0 | 2 |
| Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with subfertility | 31.7 | 0 | 2 |
| Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction cycles | 31.7 | 0 | 2 |
| Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with subfertility | 31.7 | 0 | 2 |
| The use of complementary and alternative fertility treatment in couples seeking fertility care: data from a prospective cohort in the United States | 31.7 | 0 | 2 |
| Human chorionic gonadotropin administration is associated with high pregnancy rates during ovarian stimulation and timed intercourse or intrauterine insemination | 31.7 | 0 | 2 |
| Journal of Experimental & Clinical Assisted Reproduction: shaping the future of research and practice in reproductive endocrinology/infertility | 31.7 | 0 | 2 |
| The role of aromatase inhibitors in ameliorating deleterious effects of ovarian stimulation on outcome of infertility treatment | 31.7 | 0 | 2 |
| In vitromaturation of human oocytes: Its role in infertility treatment and new possibilities | 31.7 | 0 | 2 |
| Effectiveness of GnRH Antagonist in the Management of Subfertile Couples Undergoing Controlled Ovarian Stimulation and Intrauterine Insemination: A Meta-Analysis | 31.7 | 0 | 2 |
| Q28344605 | 31.7 | 0 | 2 |
| Assessment of multiple intrauterine gestations from ovarian stimulation (AMIGOS) trial: baseline characteristics | 31.7 | 0 | 2 |
| Predictors of participant retention in infertility treatment trials | 31.7 | 0 | 2 |
| Human spermatozoa ultrastructure assessment in the infertility treatment by assisted reproduction technique | 31.7 | 0 | 2 |
| The influence of the number of follicles on pregnancy rates in intrauterine insemination with ovarian stimulation: a meta-analysis. | 31.7 | 0 | 2 |
| Fertility treatments and outcomes among couples seeking fertility care: data from a prospective fertility cohort in the United States | 31.7 | 0 | 2 |
| Assisted reproduction-in vitro fertilization success is improved by ovarian stimulation with exogenous gonadotropins and pituitary suppression with gonadotropin-releasing hormone analogues | 31.7 | 0 | 2 |
| Corifollitropin alfa compared to daily rFSH or HP-HMG in GnRH antagonist controlled ovarian stimulation protocol for patients undergoing assisted reproduction. | 31.7 | 0 | 2 |
| Follicle-stimulating hormone and human menopausal gonadotropin for ovarian stimulation in assisted reproduction cycles | 31.7 | 0 | 2 |
| Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction cycles. | 31.7 | 0 | 2 |
| How the FMR1 gene became relevant to female fertility and reproductive medicine | 31.7 | 0 | 2 |
| Minimal ovarian stimulation (mini-IVF) for IVF utilizing vitrification and cryopreserved embryo transfer | 31.7 | 0 | 2 |
| Ovarian stimulation during the luteal phase for fertility preservation of cancer patients: case reports and review of the literature | 31.7 | 0 | 2 |
| Ovarian tissue cryopreservation followed by controlled ovarian stimulation and pick-up of mature oocytes does not impair the number or quality of retrieved oocytes | 31.7 | 0 | 2 |
| Risk of thrombosis in women with malignancies undergoing ovarian stimulation for fertility preservation | 31.7 | 0 | 2 |
| Age, body mass index, and number of previous trials: are they prognosticators of intra-uterine-insemination for infertility treatment? | 31.7 | 0 | 2 |
| Updated meta-analysis of recombinant follicle-stimulating hormone (FSH) versus urinary FSH for ovarian stimulation in assisted reproduction | 31.7 | 0 | 2 |
| Deep intrauterine insemination and embryo transfer in pigs. | 31.7 | 0 | 2 |
| Access to fertility treatment by gays, lesbians, and unmarried persons: a committee opinion | 31.7 | 0 | 2 |
| Bilateral ovarian pregnancy after intrauterine insemination and controlled ovarian stimulation | 31.7 | 0 | 2 |
| Prevention of multiple pregnancies in couples with unexplained or mild male subfertility: randomised controlled trial of in vitro fertilisation with single embryo transfer or in vitro fertilisation in modified natural cycle compared with intrauterin | 31.7 | 0 | 2 |
| Intrauterine insemination with or without mild ovarian stimulation in couples with male subfertility due to oligo/astheno- and/or teratozoospermia or antisperm antibodies: a prospective cross-over trial. | 31.7 | 0 | 2 |
| Fertility treatment when the prognosis is very poor or futile | 31.7 | 0 | 2 |
| Access to fertility treatment by gays, lesbians, and unmarried persons | 31.7 | 0 | 2 |
| Ovarian stimulation in patients with breast cancer | 31.7 | 0 | 2 |
| Ovarian stimulation and in-vitro fertilization outcomes of cancer patients undergoing fertility preservation compared to age matched controls: a 17-year experience | 31.7 | 0 | 2 |
| Thromboembolism after ovarian stimulation: successful management of a woman with superior sagittal sinus thrombosis after IVF and embryo transfer: Case report | 31.7 | 0 | 2 |
| Choice of ovarian stimulation regimens in assisted reproduction: finding the thread in the gonadotropin maze | 31.7 | 0 | 2 |
| Ovarian stimulation for emergency fertility preservation in cancer patients: A case series study | 31.7 | 0 | 2 |
| Intrauterine insemination: a UK survey on the adherence to NICE clinical guidelines by fertility clinics | 31.7 | 0 | 2 |
| Optimal timing for elective egg freezing | 31.7 | 0 | 2 |
| Ovarian stimulation and embryo banking for fertility preservation in a woman with severe mixed connective tissue disease: is it safe? | 31.7 | 0 | 2 |
| What is the most relevant standard of success in assisted reproduction? Redefining success in the context of elective single embryo transfer: evidence, intuition and financial reality | 31.7 | 0 | 2 |
| Fertility Preservation Success Subsequent to Concurrent Aromatase Inhibitor Treatment and Ovarian Stimulation in Women With Breast Cancer | 31.7 | 0 | 2 |
| The best infertility treatment for vasectomized men: assisted reproduction or vasectomy reversal? | 31.7 | 0 | 2 |
| Human recombinant follicle stimulating hormone (rFSH) compared to urinary human menopausal gonadotropin (HMG) for ovarian stimulation in assisted reproduction: a literature review and cost evaluation | 31.7 | 0 | 2 |
| Gonadotrophin ovarian stimulation and intrauterine insemination for unexplained infertility | 31.7 | 0 | 2 |
| Minimal ovarian stimulation combined with elective single embryo transfer policy: age-specific results of a large, single-centre, Japanese cohort | 31.7 | 0 | 2 |
| The association of serum estradiol level with outcomes of clomiphene citrate/human menopausal gonadotropin ovarian stimulation for in vitro fertilization and embryo transfer | 31.7 | 0 | 2 |
| Effect of endometrial biopsy on intrauterine insemination outcome in controlled ovarian stimulation cycle | 31.7 | 0 | 2 |
| Doctors' Preferences for Controlled Ovarian Stimulation Protocols in Intrauterine Insemination | 31.7 | 0 | 2 |
| Outcomes of ovarian stimulation after treatment with chemotherapy | 31.7 | 0 | 2 |
| Soft versus firm embryo transfer catheters for assisted reproduction: a systematic review and meta-analysis | 31.7 | 0 | 2 |
| Conservative management versus aspiration of functional ovarian cysts before ovarian stimulation for assisted reproduction | 31.7 | 0 | 2 |
| Mature oocyte retrieval during laparotomic debulking surgery following random-start controlled ovarian stimulation for fertility preservation in a patient with suspected ovarian cancer | 31.7 | 0 | 2 |
| A global perspective on assisted reproductive technology fertility treatment: an 8-country fertility specialist survey | 31.7 | 0 | 2 |
| Firm embryo transfer catheters for assisted reproduction: a systematic review and meta-analysis using direct and adjusted indirect comparisons | 31.7 | 0 | 2 |
| Oncofertility: a grand collaboration between reproductive medicine and oncology | 31.7 | 0 | 2 |
| Intrauterine insemination catheters for assisted reproduction: a systematic review and meta-analysis | 31.7 | 0 | 2 |
| Guidelines for reducing the risk of viral transmission during fertility treatment | 31.7 | 0 | 2 |
| The Effects of Total Motile Sperm Count on Spontaneous Pregnancy Rate and Pregnancy After IUI Treatment in Couples with Male Factor and Unexplained Infertility | 31.7 | 0 | 2 |
| Reluctance of medical professionals in adopting natural-cycle and minimal ovarian stimulation protocols in human clinical assisted reproduction | 31.7 | 0 | 2 |
| Random-start controlled ovarian stimulation for emergency fertility preservation in a patient with myelodysplastic syndrome: a case report | 31.7 | 0 | 2 |
| Use of letrozole in assisted reproduction: a systematic review and meta-analysis. | 31.7 | 0 | 2 |
| Estimating rates of multiple gestation pregnancies: sample size calculation from the assessment of multiple intrauterine gestations from ovarian stimulation (AMIGOS) trial | 31.7 | 0 | 2 |
| Comparison of the GnRH agonist and antagonist protocol on the same patients in assisted reproduction during controlled ovarian stimulation cycles | 31.7 | 0 | 2 |
| Assisted reproduction and fertility preservation techniques in cancer patients | 31.7 | 0 | 2 |
| Optimizing natural fertility | 31.7 | 0 | 2 |
| Blastocyst culture and transfer in clinical-assisted reproduction | 31.7 | 0 | 2 |
| Endometrial signaling pathways during ovarian stimulation for assisted reproduction technology | 31.7 | 0 | 2 |
| Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients | 31.7 | 0 | 2 |
| Economics of assisted reproduction: access to fertility treatments and valuing live births in economic terms | 31.7 | 0 | 2 |
| Attitudes towards single embryo transfer, twin and higher order pregnancies in patients undergoing infertility treatment: a review | 31.7 | 0 | 2 |
| Human immunodeficiency virus and infertility treatment | 31.7 | 0 | 2 |
| Clinical recommendation on fertility preservation in borderline ovarian neoplasm: ovarian stimulation and oocyte retrieval after conservative surgery | 31.7 | 0 | 2 |
| Fertility preservation and infertility treatment in breast cancer patients | 31.7 | 0 | 2 |
| The promise of in vitro maturation in assisted reproduction and fertility preservation. | 31.7 | 0 | 2 |
| Corifollitropin alfa: a review of its use in controlled ovarian stimulation for assisted reproduction | 31.7 | 0 | 2 |
| Elective single-embryo transfer | 31.7 | 0 | 2 |
| Does exogenous LH in ovarian stimulation improve assisted reproduction success? An appraisal of the literature | 31.7 | 0 | 2 |
| Ovarian stimulation and intrauterine insemination at the quarter centennial: implications for the multiple births epidemic | 31.7 | 0 | 2 |
| Ovarian stimulation and fertility preservation with the use of aromatase inhibitors in women with breast cancer | 31.7 | 0 | 2 |
| Ovarian stem cells—Potential roles in infertility treatment and fertility preservation | 31.7 | 0 | 2 |
| Blastocyst culture and transfer in clinical-assisted reproduction: a committee opinion | 31.7 | 0 | 2 |
| The wobbly evidence base of reproductive medicine | 31.7 | 0 | 2 |
| Misconduct in third-party assisted reproduction: a committee opinion | 31.7 | 0 | 2 |
| Methods employed to overcome difficult embryo transfer during assisted reproduction treatment | 31.7 | 0 | 2 |
| Evaluating the performance of serum antimullerian hormone concentration in predicting the live birth rate of controlled ovarian stimulation and intrauterine insemination | 31.7 | 0 | 2 |
| Evidence of impaired endometrial receptivity after ovarian stimulation for in vitro fertilization: a prospective randomized trial comparing fresh and frozen–thawed embryo transfer in normal responders | 31.7 | 0 | 2 |
| Comparison of follicular fluid IGF-I, IGF-II, IGFBP-3, IGFBP-4 and PAPP-A concentrations and their ratios between GnRH agonist and GnRH antagonist protocols for controlled ovarian stimulation in IVF-embryo transfer patients | 31.7 | 0 | 2 |
| Subclinical hypothyroidism in the infertile female population: a guideline | 31.7 | 0 | 2 |
| Comparison of neonatal outcomes following progesterone use during ovarian stimulation with frozen-thawed embryo transfer | 31.7 | 0 | 2 |
| Random Start Ovarian Stimulation for Oocyte or Embryo Cryopreservation in Women Desiring Fertility Preservation Prior to Gonadotoxic Cancer Therapy | 31.7 | 0 | 2 |
| The effect of peri-implantation administration of uterine relaxing agents in assisted reproduction treatment cycles: a systematic review and meta-analysis | 31.7 | 0 | 2 |
| Fertility preservation in female oncology patients: the influence of the type of cancer on ovarian stimulation response | 31.7 | 0 | 2 |
| Embryo transfer techniques: an American Society for Reproductive Medicine survey of current Society for Assisted Reproductive Technology practices | 31.7 | 0 | 2 |
| Predictive factors for pregnancy outcome following controlled ovarian stimulation and intrauterine insemination | 31.7 | 0 | 2 |
| Embryo transfer simulation improves pregnancy rates and decreases time to proficiency in Reproductive Endocrinology and Infertility fellow embryo transfers | 31.7 | 0 | 2 |
| Ovarian Stimulation, Intrauterine Insemination, Multiple Pregnancy and Major Congenital Malformations: A Systematic Review and Meta- Analysis- The ART_Rev Study | 31.7 | 0 | 2 |
| Performing the embryo transfer: a guideline | 31.7 | 0 | 2 |
| Effect of smoking on ovarian reserve and ovarian stimulation in in- vitro fertilization and embryo transfer | 31.7 | 0 | 2 |
| Fertility preservation and reproduction in patients facing gonadotoxic therapies: a committee opinion | 31.7 | 0 | 2 |
| The case for aromatase inhibitors use in Oncofertility patients. Should aromatase inhibitors be combined with gonadotropin treatment in Breast Cancer patients undergoing ovarian stimulation for fertility preservation prior to chemotherapy? A debate | 31.7 | 0 | 2 |
| Ovarian stimulation with clomiphene and/or human menopausal gonadotropin (HMG) for in vitro fertilization (IVF) and embryo transfer (ET). | 31.7 | 0 | 2 |
| In vitro maturation improves oocyte or embryo cryopreservation outcome in breast cancer patients undergoing ovarian stimulation for fertility preservation. | 31.7 | 0 | 2 |
| Assisted reproductive medicine in Poland --Fertility and Sterility Special Interest Group of the Polish Gynaecological Society (SPiN PTG) 2012 report | 31.7 | 0 | 2 |
| Luteal-phase ovarian stimulation is a feasible method for poor ovarian responders undergoing in vitro fertilization/intracytoplasmic sperm injection-embryo transfer treatment compared to a GnRH antagonist protocol: A retrospective study | 31.7 | 0 | 2 |
| Determining the need for rescue intracytoplasmic sperm injection in partial fertilisation failure during a conventional IVF cycle | 31.7 | 0 | 2 |
| Catastrophic payment for assisted reproduction techniques with conventional ovarian stimulation in the public health sector of South Africa: frequency and coping strategies | 31.7 | 0 | 2 |
| Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos? | 31.7 | 0 | 2 |
| Assisted reproduction policies in Israel: a retrospective analysis of in vitro fertilization–embryo transfer | 31.7 | 0 | 2 |
| Is there an effect of thyroid autoimmunity on the outcomes of assisted reproduction? | 31.7 | 0 | 2 |
| Fertility preservation and reproduction in cancer patients | 31.7 | 0 | 2 |
| Cycle-to-cycle variation in utero-ovarian hemodynamic indices in ovarian stimulation and natural cycles of the same women and its effect on the outcome of assisted reproduction treatment. | 31.7 | 0 | 2 |
| Luteinizing hormone-releasing hormone agonists for ovarian stimulation in assisted reproduction | 31.7 | 0 | 2 |
| Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction | 31.7 | 0 | 2 |
| Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients. | 31.7 | 0 | 2 |
| Therapeutic intrauterine insemination improves with gonadotropin ovarian stimulation | 31.7 | 0 | 2 |
| Ovarian stimulation for assisted reproduction | 31.7 | 0 | 2 |
| The Effects of Mandated Health Insurance Benefits for Autism on Out-of-Pocket Costs and Access to Treatment | 31.7 | 0 | 2 |
| Mole modifications following controlled ovarian stimulation for assisted reproduction technologies | 31.7 | 0 | 2 |
| Comparison of live-birth defects after luteal-phase ovarian stimulation vs. conventional ovarian stimulation for in vitro fertilization and vitrified embryo transfer cycles | 31.7 | 0 | 2 |
| Impact of single embryo transfer policy on perinatal outcomes in fresh and frozen cycles—analysis of the Japanese Assisted Reproduction Technology registry between 2007 and 2012 | 31.7 | 0 | 2 |
| Human immunodeficiency virus (HIV) and infertility treatment: a committee opinion | 31.7 | 0 | 2 |
| Ovarian stimulation in assisted reproduction. | 31.7 | 0 | 2 |
| Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trials | 31.7 | 0 | 2 |
| Neonatal outcome and birth defects in 6623 singletons born following minimal ovarian stimulation and vitrified versus fresh single embryo transfer | 31.7 | 0 | 2 |
| Fertility preservation by ovarian stimulation and oocyte cryopreservation in a 14-year-old adolescent with Turner syndrome mosaicism and impending premature ovarian failure | 31.7 | 0 | 2 |
| Lapse in embryo transfer training does not negatively affect clinical pregnancy rates for reproductive endocrinology and infertility fellows | 31.7 | 0 | 2 |
| Gonadotropin Alone is a Better Drug for Ovarian Stimulation than in Combination with Clomiphene in Intrauterine Insemination | 31.7 | 0 | 2 |
| Ovarian stimulation and corpus luteum function in human in vitro fertilization and embryo transfer | 31.7 | 0 | 2 |
| Preprogrammed, unmonitored ovarian stimulation reduces expense without compromising the outcome of assisted reproduction | 31.7 | 0 | 2 |
| Treatment of infertile women with unilateral tubal occlusion by intrauterine insemination and ovarian stimulation | 31.7 | 0 | 2 |
| Delivery rates following IVF treatment, using two recombinant FSH preparations for ovarian stimulation | 31.7 | 0 | 2 |
| IVF Treatment and Single Embryo Transfer | 31.7 | 0 | 2 |
| Preconception Steroid Treatment in Infertile Women with Antithyroid Autoimmunity Undergoing Ovarian Stimulation and Intrauterine Insemination: A Double-Blind, Randomized, Prospective Cohort Study | 31.7 | 0 | 2 |
| Lyophilised hMG versus rFSH in women with unexplained infertility undergoing a controlled ovarian stimulation with intrauterine insemination: a prospective, randomised study. | 31.7 | 0 | 2 |
| Ovarian stimulation and emergency in vitro fertilization for fertility preservation in cancer patients | 31.7 | 0 | 2 |
| First live birth following IVF-embryo transfer and use of GnRHa alone for ovarian stimulation | 31.7 | 0 | 2 |
| Refuting a misguided campaign against the goal of single-embryo transfer and singleton birth in assisted reproduction | 31.7 | 0 | 2 |
| Usage of herbal medications in patients undergoing IVF treatment in an Irish infertility treatment unit | 31.7 | 0 | 2 |
| Comparison of 2 therapeutic strategies in severe endometriosis, in young women consulting for sterility or pain. II. In the case of infertility, value of ovarian stimulation with intrauterine insemination after surgery | 31.7 | 0 | 2 |
| Optimizing natural fertility: a committee opinion | 31.7 | 0 | 2 |
| Life after unsuccessful IVF treatment in an assisted reproduction unit: a qualitative analysis of gains through loss among Chinese persons in Hong Kong. | 31.7 | 0 | 2 |
| Suppression of LH during ovarian stimulation: analysing threshold values and effects on ovarian response and the outcome of assisted reproduction in down-regulated women stimulated with recombinant FSH. | 31.7 | 0 | 2 |
| Recommendations for reducing the risk of viral transmission during fertility treatment with the use of autologous gametes: a committee opinion | 31.7 | 0 | 2 |
| Acceptability and value of autoinjection of gonadotropins for ovarian stimulation in intrauterine insemination | 31.7 | 0 | 2 |
| The relationship between endogenous oestradiol and vitamin D3 metabolites in serum and follicular fluid during ovarian stimulation for in-vitro fertilization and embryo transfer | 31.7 | 0 | 2 |
| The effect of smoking on infertility treatment in women undergoing assisted reproduction cycles | 31.7 | 0 | 2 |
| Ovarian stimulation in intrauterine insemination with donor sperm: a randomized study comparing clomiphene citrate in fixed protocol versus highly purified urinary FSH. | 31.7 | 0 | 2 |
| Intrauterine insemination with frozen donor sperm. Pregnancy outcome in relation to age and ovarian stimulation regime | 31.7 | 0 | 2 |
| Cycle-specific and cumulative fecundity in patients with endometriosis who are undergoing controlled ovarian hyperstimulation-intrauterine insemination or in vitro fertilization-embryo transfer | 31.7 | 0 | 2 |
| Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen | 31.7 | 0 | 2 |
| Personal experience with ovarian stimulation in an in vitro fertilization and embryo transfer program | 31.7 | 0 | 2 |
| The serum concentration of estradiol after embryo transfer and the decline from preovulatory levels may influence the success of IVF treatment | 31.7 | 0 | 2 |
| The significance of the ionophore-challenged acrosome reaction in the prediction of successful outcome of controlled ovarian stimulation and intrauterine insemination | 31.7 | 0 | 2 |
| Optimal treatment for poor responders to ovarian stimulation: does in vitro insemination offer any advantages to intrauterine insemination? | 31.7 | 0 | 2 |
| Prognostic factors for successful outcome in patients undergoing controlled ovarian stimulation and intrauterine insemination | 31.7 | 0 | 2 |
| LH serum levels during ovarian stimulation as predictors of ovarian response and assisted reproduction outcome in down-regulated women stimulated with recombinant FSH. | 31.7 | 0 | 2 |
| Effect of ovarian stimulation on plasma lipid and apolipoprotein concentrations in a population of infertile women undergoing IVF/embryo transfer | 31.7 | 0 | 2 |
| Letrozole co-treatment in infertile women 40 years old and older receiving controlled ovarian stimulation and intrauterine insemination | 31.7 | 0 | 2 |
| IVF with planned single-embryo transfer versus IUI with ovarian stimulation in couples with unexplained subfertility: an economic analysis | 31.7 | 0 | 2 |
| Ovarian stimulation for in vitro fertilization and embryo transfer, human menopausal gonadotropin versus pure human follicle stimulating hormone: a randomized prospective study. | 31.7 | 0 | 2 |
| Half-dose depot triptorelin in pituitary suppression for multiple ovarian stimulation in assisted reproduction technology: a randomized study | 31.7 | 0 | 2 |
| Embryo transfer by reproductive endocrinology fellows vs attending physicians: are live birth rates comparable? | 31.7 | 0 | 2 |
| Comparison of clinical outcome of mild-stimulation and conventional ovarian stimulation in in vitro fertilization-embryo transfer (IVF-ET) | 31.7 | 0 | 2 |
| Perspective on in vitro fertilization and embryo transfer. Stimulus for biomedical research in reproductive medicine | 31.7 | 0 | 2 |
| A higher anti-Müllerian hormone level is associated with an increased chance of pregnancy in patients undergoing controlled ovarian stimulation and intrauterine insemination | 31.7 | 0 | 2 |
| Advantages of recombinant follicle-stimulating hormone over human menopausal gonadotropin for ovarian stimulation in intrauterine insemination: a randomized clinical trial in unexplained infertility. | 31.7 | 0 | 2 |
| First pregnancy and live birth resulting from cryopreserved embryos obtained from in vitro matured oocytes after oophorectomy in an ovarian cancer patient | 31.7 | 0 | 2 |
| Human immunodeficiency virus and infertility treatment | 31.7 | 0 | 2 |
| Human immunodeficiency virus and infertility treatment | 31.7 | 0 | 2 |
| Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation | 31.7 | 0 | 2 |
| Response to 'Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors?'. | 31.7 | 0 | 2 |
| Public policy aspects of assisted reproduction. Vth World Congress, IVF and embryo transfer | 31.7 | 0 | 2 |
| Is letrozole superior to clomiphene for ovarian stimulation prior to intrauterine insemination? | 31.7 | 0 | 2 |
| Progesterone supplementation during the luteal phase and in early pregnancy in the treatment of infertility: an educational bulletin | 31.7 | 0 | 2 |
| Ovarian stimulation, egg aspiration, in vitro fertilization and embryo transfer in the baboon (Papio anubis): a pilot project at the Institute of Primate Research, Nairobi, Kenya | 31.7 | 0 | 2 |
| Random start ovarian stimulation for fertility preservation appears unlikely to delay initiation of neoadjuvant chemotherapy for breast cancer | 31.7 | 0 | 2 |
| Intrauterine insemination of cultured peripheral blood mononuclear cells prior to embryo transfer improves clinical outcome for patients with repeated implantation failures | 31.7 | 0 | 2 |
| The effect of ovarian stimulation on the outcome of intrauterine insemination | 31.7 | 0 | 2 |
| Ovarian stimulation for fertility preservation in patients with cancer | 31.7 | 0 | 2 |
| Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation | 31.7 | 0 | 2 |
| The effect of elevated progesterone levels before oocyte retrieval in women undergoing ovarian stimulation for IVF treatment on the genomic profile of peri-implantation endometrium. | 31.7 | 0 | 2 |
| Effective method for emergency fertility preservation: random-start controlled ovarian stimulation | 31.7 | 0 | 2 |
| Women with ovulatory dysfunction undergoing ovarian stimulation with clomiphene citrate for intrauterine insemination may benefit from administration of human chorionic gonadotropin | 31.7 | 0 | 2 |
| Intrauterine insemination with controlled ovarian stimulation for treatment of infertility: an audit of a new IUI programme in a low resource setting | 31.7 | 0 | 2 |
| Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing in vitro fertilization to cryopreserve their embryos for fertility preservation | 31.7 | 0 | 2 |
| Evolution of a reproductive endocrinologist: the Society for Reproductive Endocrinology and Infertility fellows retreat and preliminary results of manpower survey | 31.7 | 0 | 2 |
| A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine inseminatio | 31.7 | 0 | 2 |
| Posthumous assisted reproduction: a survey of attitudes of couples seeking fertility treatment and the degree of agreement between intimate partners | 31.7 | 0 | 2 |
| Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study | 31.7 | 0 | 2 |
| Viral infections among couples for assisted reproduction in a fertility clinic in Nigeria. | 31.7 | 0 | 2 |
| Erratum to: Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy | 31.7 | 0 | 2 |
| Factors associated with dizygotic twinning after IVF treatment with double embryo transfer | 31.7 | 0 | 2 |
| The significance of antral follicle count in controlled ovarian stimulation and intrauterine insemination | 31.7 | 0 | 2 |
| Fertility preservation with ovarian stimulation protocols prior to cancer treatment | 31.7 | 0 | 2 |
| Racial Disparities in Fertility Care: an Analysis of 4537 Intrauterine Insemination Cycles | 31.7 | 0 | 2 |
| Effect of letrozole at 2.5 mg or 5.0 mg/day on ovarian stimulation with gonadotropins in women undergoing intrauterine insemination | 31.7 | 0 | 2 |
| Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion | 31.7 | 0 | 2 |
| The SUPER study: protocol for a randomised controlled trial comparing follicle-stimulating hormone and clomiphene citrate for ovarian stimulation in intrauterine insemination | 31.7 | 0 | 2 |
| Medical egg freezing: the importance of a patient-centered approach to fertility preservation | 31.7 | 0 | 2 |
| Medical egg freezing and cancer patients' hopes: Fertility preservation at the intersection of life and death | 31.7 | 0 | 2 |
| Intrauterine insemination with ovarian stimulation versus expectant management for unexplained infertility (TUI): a pragmatic, open-label, randomised, controlled, two-centre trial | 31.7 | 0 | 2 |
| Reprotoxicity of intrauterine insemination and in vitro fertilization-embryo transfer disposables and products: a 4-year survey | 31.7 | 0 | 2 |
| Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy | 31.7 | 0 | 2 |
| Ovarian response to controlled ovarian stimulation for fertility preservation before oncology treatment: A retrospective cohort of 157 patients | 31.7 | 0 | 2 |
| Does ovarian stimulation regimen affect IVF outcome? a two-centre, real-world retrospective study using predominantly cleavage-stage, single embryo transfer | 31.7 | 0 | 2 |
| The Importance of the Periconception Period: Immediate Effects in Cattle Breeding and in Assisted Reproduction Such as Artificial Insemination and Embryo Transfer | 31.7 | 0 | 2 |
| Provision of fertility services for women at increased risk of complications during fertility treatment or pregnancy: an Ethics Committee opinion | 31.7 | 0 | 2 |
| The impact of ovarian stimulation on the outcome of intrauterine insemination treatment: an analysis of 8893 cycles | 31.7 | 0 | 2 |
| The impact of the new Turkish regulation, imposing single embryo transfer after assisted reproduction technology, on neonatal intensive care unit utilization: a single center experience. | 31.7 | 0 | 2 |
| Successful controlled ovarian stimulation despite elevated hCG levels after first-trimester abortion in the context of fertility preservation | 31.7 | 0 | 2 |
| Double ovarian stimulation (DuoStim) protocol for fertility preservation in female oncology patients | 31.7 | 0 | 2 |
| First line fertility treatment strategies regarding IUI and IVF require clinical evidence | 31.7 | 0 | 2 |
| Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing ovarian stimulation for fertility preservation. | 31.7 | 0 | 2 |
| Ovarian Stimulation in Patients With Cancer: Impact of Letrozole and BRCA Mutations on Fertility Preservation Cycle Outcomes | 31.7 | 0 | 2 |
| The use of luteal-phase ovarian stimulation for poor ovarian responders undergoing in vitro fertilization/intracytoplasmic sperm injection-embryo transfer treatment | 31.7 | 0 | 2 |
| Long-acting recombinant follicle-stimulating hormone in random-start ovarian stimulation protocols for fertility preservation in women with cancer | 31.7 | 0 | 2 |
| A specific controlled ovarian stimulation (COS) protocol for fertility preservation in women with breast cancer undergoing neoadjuvant chemotherapy | 31.7 | 0 | 2 |
| Do endometriomas grow during ovarian stimulation for assisted reproduction? A three-dimensional volume analysis before and after ovarian stimulation | 31.7 | 0 | 2 |
| The psychological impact of mild ovarian stimulation combined with single embryo transfer compared with conventional IVF. | 31.7 | 0 | 2 |
| Cryopreserved embryo transfer: adjacent or non-adjacent to failed fresh long GnRH-agonist protocol IVF cycle | 31.7 | 0 | 2 |
| There is no evidence that the time from egg retrieval to embryo transfer affects live birth rates in a freeze-all strategy | 31.7 | 0 | 2 |
| Predictive value of anti-müllerian hormone, follicle-stimulating hormone and antral follicle count on the outcome of ovarian stimulation in women following GnRH-antagonist protocol for IVF/ET | 31.7 | 0 | 2 |
| Self-operated endovaginal telemonitoring versus traditional monitoring of ovarian stimulation in assisted reproduction: an RCT | 31.7 | 0 | 2 |
| The impact of legally restricted embryo transfer and reimbursement policy on cumulative delivery rate after treatment with assisted reproduction technology | 31.7 | 0 | 2 |
| Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles | 31.7 | 0 | 2 |
| Colour Doppler assessment of ascendent uterine artery perfusion in an in-vitro fertilization-embryo transfer programme after pituitary desensitization and ovarian stimulation with human recombinant follicle stimulating hormone | 31.7 | 0 | 2 |
| Effects of cancer on ovarian response in controlled ovarian stimulation for fertility preservation | 31.7 | 0 | 2 |
| The effects of letrozole on ovarian stimulation for fertility preservation in cancer-affected women. | 31.7 | 0 | 2 |
| Improving fertility preservation in cancer: ovarian tissue cryobanking followed by ovarian stimulation can be efficiently combined. | 31.7 | 0 | 2 |
| Intermittent vaginal injections of gonadotrophins for ovarian stimulation in IVF treatment | 31.7 | 0 | 2 |
| Predictors of ongoing pregnancy after single-embryo transfer following mild ovarian stimulation for IVF. | 31.7 | 0 | 2 |
| New alternative to infertility treatment for women without ovarian stimulation. | 31.7 | 0 | 2 |
| Similar outcome for cryopreserved embryo transfer following GnRH-antagonist/GnRH-agonist, GnRH-antagonist/HCG or long protocol ovarian stimulation | 31.7 | 0 | 2 |
| Assisted reproduction technique outcomes for fresh versus deferred cryopreserved day-2 embryo transfer: a retrospective matched cohort study | 31.7 | 0 | 2 |
| Ovarian stimulation during assisted reproduction treatment: a comparison of recombinant and highly purified urinary human FSH. On behalf of The Feronia and Apis study group | 31.7 | 0 | 2 |
| Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study | 31.7 | 0 | 2 |
| Ovarian stimulation in women undergoing in-vitro fertilization and embryo transfer using recombinant human follicle stimulating hormone (Gonal-F) in non-down-regulated cycles | 31.7 | 0 | 2 |
| Endocrinology: Endogenous plasma growth hormone and the occurrence of pregnancies in patients undergoing in-vitro fertilization and embryo transfer with ovarian stimulation | 31.7 | 0 | 2 |
| Selection of ovarian stimulation protocol is related to IVF treatment outcome in women 35 years of age and older | 31.7 | 0 | 2 |
| Bilateral salpingectomy does not compromise ovarian stimulation in an in-vitro fertilization/embryo transfer programme | 31.7 | 0 | 2 |
| Growth hormone, oestradiol, progesterone and testosterone concentrations in follicular fluid after ovarian stimulation with various regimes for assisted reproduction | 31.7 | 0 | 2 |
| Birthweight of singletons after assisted reproduction is higher after single- than after double-embryo transfer | 31.7 | 0 | 2 |
| Successful Ovarian Stimulation for Fertility Preservation in a Patient with Chronic Myeloid Leukemia: Switch from Nilotinib to Interferon-α. | 31.7 | 0 | 2 |
| Infertility treatment strategy involving combined freeze-all embryos and single vitrified-warmed embryo transfer during hormonal replacement cycle for in vitro fertilization of women with hypogonadotropic hypogonadism | 31.7 | 0 | 2 |
| At the dawn of personalized reproductive medicine: opportunities and challenges with incorporating multigene panel testing into fertility care | 31.7 | 0 | 2 |
| Role of FSHR rs6165 and ESR2 rs4986938 polymorphisms in ovarian stimulation of Iranian women who underwent assisted reproduction treatment | 31.7 | 0 | 2 |
| Comparison of embryo transfer strategies and assisted reproduction outcome in Slovenian and cross-border patients | 31.7 | 0 | 2 |
| Cost-effectiveness of ovarian stimulation with gonadotrophin and clomiphene citrate in an intrauterine insemination programme for subfertile couples. | 31.7 | 0 | 2 |
| CLINICAL ASSISTED REPRODUCTION: Comparison of Recombinant and Urinary Follicle-Stimulating Hormone Preparations in Short-Term Gonadotropin Releasing Hormone Agonist Protocol for In Vitro Fertilization-Embryo Transfer | 31.7 | 0 | 2 |
| Bioethical dilemmas of assisted reproduction in the opinions of Polish women in infertility treatment: a research report | 31.7 | 0 | 2 |
| Costs of medically assisted reproduction treatment at specialized fertility clinics in the Danish public health care system: results from a 5-year follow-up cohort study | 31.7 | 0 | 2 |
| Perinatal outcomes in 6,338 singletons born after intrauterine insemination in Denmark, 2007 to 2012: the influence of ovarian stimulation | 31.7 | 0 | 2 |
| Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers | 31.7 | 0 | 2 |
| Use of serum inhibin B levels at the start of ovarian stimulation and at oocyte pickup in the prediction of assisted reproduction treatment outcome | 31.7 | 0 | 2 |
| Use of fetal oocytes in assisted reproduction | 31.7 | 0 | 2 |
| Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction | 31.7 | 0 | 2 |
| Cetrotide confirmatory trial of cetrorelix/0.25 mg in 26 women undergoing ovarian stimulation with recombinant follicle stimulating hormones for IVF, ICSI and embryo transfer (ET). | 31.7 | 0 | 2 |
| Changes induced in serum protein profiles by ovarian stimulation during in-vitro fertilization--embryo transfer treatment: a comparison between conception and non-conception cycles | 31.7 | 0 | 2 |
| Further observations on serial serum immunoreactive inhibin levels in the luteal phase and early gestation after ovarian stimulation for in vitro fertilization and embryo transfer | 31.7 | 0 | 2 |
| Comparison of four different ovarian stimulation protocols in an in vitro fertilisation & embryo transfer programme | 31.7 | 0 | 2 |
| Optimizing natural fertility: a committee opinion | 31.7 | 0 | 2 |
| Expectations for success in fertility treatment involving assisted reproduction | 31.7 | 0 | 2 |
| Reproductive medicine in transition: new developments in embryo transfer | 31.7 | 0 | 2 |
| Efficacy of intrauterine inseminations as a training modality for performing embryo transfer in reproductive endocrinology and infertility fellowship programs. | 31.7 | 0 | 2 |
| Clinical experience with an ovarian stimulation protocol for intrauterine insemination adopting a gonadotropin releasing hormone antagonist at low dose. | 31.7 | 0 | 2 |
| Is there a need for recombinant human luteinizing hormone (lutropin alfa) supplementation in ovarian stimulation for assisted reproduction? | 31.7 | 0 | 2 |
| Gonadotropin-releasing hormone antagonist use in controlled ovarian stimulation and intrauterine insemination cycles in women with polycystic ovary syndrome | 31.7 | 0 | 2 |
| Effectiveness of intrauterine insemination in subfertile couples with an isolated cervical factor: a randomized clinical trial | 31.7 | 0 | 2 |
| Predictive factors and a corresponding treatment algorithm for controlled ovarian stimulation in patients treated with recombinant human follicle stimulating hormone (follitropin alfa) during assisted reproduction technology (ART) procedures. An ana | 31.7 | 0 | 2 |
| AIDA for reproductive medicine and the fertility clinic | 31.7 | 0 | 2 |
| Selective early elimination of luteal support in assisted reproduction cycles using a gonadotropin-releasing hormone agonist during ovarian stimulation | 31.7 | 0 | 2 |
| Pregnancy outcomes of PCOS overweight/obese patients after controlled ovarian stimulation with the GnRH antagonist protocol and frozen embryo transfer | 31.7 | 0 | 2 |
| Beyond the American Society for Reproductive Medicine transfer guidelines: how many cleavage-stage embryos are safe to transfer in women ≥43 years old? | 31.7 | 0 | 2 |
| Anti-Müllerian hormone levels after laparoscopic cystectomy for endometriomas as a possible predictor for pregnancy in infertility treatments | 31.7 | 0 | 2 |
| AIUM practice guideline for ultrasonography in reproductive medicine | 31.7 | 0 | 2 |
| Suitable fresh embryo transfer strategy for mild ovarian stimulation with clomiphene citrate | 31.7 | 0 | 2 |
| Impact of unilateral tubal blockage diagnosed by hysterosalpingography on the success rate of treatment with controlled ovarian stimulation and intrauterine insemination | 31.7 | 0 | 2 |
| Comparison of the effect of immediate versus delayed transfer following a stimulated IVF cycle on the ongoing pregnancy rate of frozen-thawed embryo transfer cycles: a study protocol for a randomised controlled trial. | 31.7 | 0 | 2 |
| Trust women to choose: a response to John a Robertson's 'Egg freezing and Egg banking: empowerment and alienation in assisted reproduction'. | 31.7 | 0 | 2 |
| Ovarian stimulation length, number of follicles higher than 17 mm and estradiol on the day of human chorionic gonadotropin administration are risk factors for multiple pregnancy in intrauterine insemination | 31.7 | 0 | 2 |
| Prospective assessment of follicular growth and the oocyte cohort after ovarian stimulation for fertility preservation in 90 cancer patients versus 180 matched controls | 31.7 | 0 | 2 |
| Fertility preservation and reproduction in patients facing gonadotoxic therapies: an Ethics Committee opinion | 31.7 | 0 | 2 |
| In-vitro fertilization (IVF), embryo transfer (ET) and assisted reproduction in the State of Israel | 31.7 | 0 | 2 |
| Reply: Low as well as high serum P4 levels in the early and mid-luteal phase reduce the chance of a live birth following IVF treatment with fresh embryo transfer | 31.7 | 0 | 2 |
| Low as well as high serum P4 levels in the early and mid-luteal phase reduce the chance of a live birth following IVF treatment with fresh embryo transfer: where is the evidence? | 31.7 | 0 | 2 |
| Abstracts for 2018 Foundation for Reproductive Medicine Translational Reproductive Biology and Clinical Reproductive Endocrinology Conference | 31.7 | 0 | 2 |
| IVF cycle cost estimation using Activity Based Costing and Monte Carlo simulation | 31.7 | 0 | 2 |
| Life-cycle cost as basis to optimize waste collection in space and time: A methodology for obtaining a detailed cost breakdown structure | 31.7 | 0 | 2 |
| Prediction of over-response to ovarian stimulation in an intrauterine insemination programme | 31.7 | 0 | 2 |
| Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors? | 31.7 | 0 | 2 |
| Misconduct in third-party assisted reproduction: an Ethics Committee opinion | 31.7 | 0 | 2 |
| THE OPTIMAL INTERVAL OF TIME FROM OPERATIVE HYSTEROSCOPY TO EMBRYO TRANSFER IN AN IVF CYCLE | 31.7 | 0 | 2 |
| Fertility preservation with random-start controlled ovarian stimulation and embryo cryopreservation for early pregnancy-associated breast cancer | 31.7 | 0 | 2 |
| Ethical obligations in fertility treatment when intimate partners withhold information from each other: an Ethics Committee opinion | 31.7 | 0 | 2 |
| Gender reassignment and assisted reproduction: An ethical analysis. Bristol Centre for Reproductive Medicine Ethics Advisory Committee | 31.7 | 0 | 2 |
| Is tissue factor pathway inhibitor a marker of procoagulable status in healthy infertile women undergoing ovarian stimulation for assisted reproduction? | 31.7 | 0 | 2 |
| The effectiveness of sublingual progesterone administration during cryopreserved embryo transfer cycles: results of a matched follow-up study**Presented in part at the 51st Annual Meeting of the American Society for Reproductive Medicine, Seattle, Wa | 31.7 | 0 | 2 |
| Predictive value of repeated measurements of luteal progesterone and estradiol levels in patients with intrauterine insemination and controlled ovarian stimulation | 31.7 | 0 | 2 |
| Controlled ovarian stimulation protocols for assisted reproduction: a network meta-analysis | 31.7 | 0 | 2 |
| Egg freezing for fertility preservation and family planning: a nationwide survey of US Obstetrics and Gynecology residents | 31.7 | 0 | 2 |
| Are we choosing the correct FSH starting dose during controlled ovarian stimulation for intrauterine insemination cycles? Potential application of a nomogram based on woman’s age and markers of ovarian reserve | 31.7 | 0 | 2 |
| GnRH antagonists and mild ovarian stimulation for intrauterine insemination: a randomized study comparing different gonadotrophin dosages | 31.7 | 0 | 2 |
| Individual Versus Standard Follicle Stimulating Hormone Dose for Controlled Ovarian Stimulation and Insemination | 31.7 | 0 | 2 |
| Study to Evaluate if the Addition of r-hLH (Luveris®) to FSH From Day 8 of Ovarian Stimulation is Able to Decrease Total FSH Dose and to Improve Cycle Outcome in Infertile Women Undergoing ART, Who Required High FSH Dose in a Previous Cycle | 31.7 | 0 | 2 |
| Single Human Embryo Transfer in Assisted Reproduction Programs | 31.7 | 0 | 2 |
| Controlled Ovarian Stimulation Followed by Timed Intercourse or Intrauterine Insemination in Infertile PCOS Patients | 31.7 | 0 | 2 |
| Can anti-Mullerian hormone (AMH) predict the outcome of intrauterine insemination with controlled ovarian stimulation? | 31.7 | 0 | 2 |
| Role of gonadotropin-releasing hormone antagonist in the management of subfertile couples with intrauterine insemination and controlled ovarian stimulation | 31.7 | 0 | 2 |
| Clinical Cohort Study on the Endocrinology and Vaginal Microbiome of the Luteal Phase in Assisted Reproduction | 31.7 | 0 | 2 |
| Comparing Ovarian Stimulation for Assisted Reproduction With Two Different Forms of Pituitary Suppression | 31.7 | 0 | 2 |
| Study to Examine Effect of Recombinant Luteinizing Hormone (r-Lh) and Recombinant Human Chorionic Gonadotropin (r-hCG) for Ovarian Stimulation in Assisted Reproduction Techniques (ART) | 31.7 | 0 | 2 |
| Luteal Phase Support With Progesterone Versus Estrogen and Progesterone on Pregnancy Rates | 31.7 | 0 | 2 |
| Does Letrozole Improve Pregnancy Outcome in Fresh Embryo Transfer IVF/ICSI Cycle? | 31.7 | 0 | 2 |
| Comparison of Blood Flow in the Arteriae Uterinae in Ovarian Stimulation Cycles | 31.7 | 0 | 2 |
| Step Up Versus Step Down in Controlled Ovarian Stimulation | 31.7 | 0 | 2 |
| Does Local Injury of the Endometrium Improve Controlled Ovarian Hyperstimulation (COH) + Intrauterine Insemination (IUI) Outcome? | 31.7 | 0 | 2 |
| Abstracts for 2017 Foundation for Reproductive Medicine Translational Reproductive Biology and Clinical Reproductive Endocrinology Conference | 31.7 | 0 | 2 |
| Neonatal outcomes following different ovarian stimulation protocols in fresh single embryo transfer | 31.7 | 0 | 2 |
| What advice should we give our patients to preserve their fertility and avoid needing oocyte donation in the future? - A Social Fertility Preservation program | 31.7 | 0 | 2 |
| Safety data for the use of nasal human menopausal gonadotropins: a potential novel approach for fertility treatment | 31.7 | 0 | 2 |
| Elective single embryo transfer in women less than age 38 years reduces multiple birth rates, but not live birth rates, in United States fertility clinics | 31.7 | 0 | 2 |
| Comparison of the Number of Oocytes Obtained Between Chinese and Caucasian Women in IVF Treatment | 31.7 | 0 | 2 |
| Random-start ovarian stimulation with aromatase inhibitor for fertility preservation in women with Japanese breast cancer | 31.7 | 0 | 2 |
| A Multicenter, Randomized, Equivalence Trial of a New Recombinant Human Chorionic Gonadotropin Preparation versus Ovitrelle for Ovulation in Women Undergoing Intrauterine Insemination Following Ovarian Stimulation | 31.7 | 0 | 2 |
| Luteal Phase Progesterone in IUI and Gonadotropin Cycles | 31.7 | 0 | 2 |
| Biomarkers of Ovarian Reserve and Correlation With IVF Treatments | 31.7 | 0 | 2 |
| A Phase III Study of FE 999913 in Japanese Female Patients Undergoing Fertility Treatment | 31.7 | 0 | 2 |
| Nimodipine to Prevent LH Surge During Ovulation Induction: Blinded Placebo-controlled RCT | 31.7 | 0 | 2 |
| Bed Rest or no Bed Rest? | 31.7 | 0 | 2 |
| Double and Single Intrauterine Insemination In Controlled Ovarian Stimulation (COH) Cycles With Multifollicular Development | 31.7 | 0 | 2 |
| Egg Freezing Pilot Study | 31.7 | 0 | 2 |
| MENOPUR in Gonadotrophin-releasing Hormone (GnRH) Antagonist Cycles With Single Embryo Transfer | 31.7 | 0 | 2 |
| How Dose Coenzyme Q10 Supplementation During Infertility Treatment Effects Pregnancy Outcome | 31.7 | 0 | 2 |
| Does Letrozole Improve the Outcomes and/or Reduce the Cost of IVF-ET Cycles? | 31.7 | 0 | 2 |
| Temporally Splitting Ovarian Stimulation and Embryo Transfer | 31.7 | 0 | 2 |
| EmbryoGlue as an Embryo Transfer Medium | 31.7 | 0 | 2 |
| The Accuracy of Endometrial Ultrasound to Predict Implantation | 31.7 | 0 | 2 |
| Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining Follicle Stimulating Hormone (FSH) and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast Cancer | 31.7 | 0 | 2 |
| Influence of Post-thaw Embryo Culture Interval on Assisted Reproduction Success Rates | 31.7 | 0 | 2 |
| Effect of Intrauterine Navigation Using Intrauterine Insemination Catheter for Mock Embryo Transfer Prior to Day 3 Embryo Transfer on Pregnancy Rate: A Pilot Study | 31.7 | 0 | 2 |
| Clinical outcomes following long GnRHa ovarian stimulation with highly purified human menopausal gonadotropin plus rFSH or rFSH in patients undergoing in vitro fertilization-embryo transfer: a multi-center randomized controlled trial. | 31.7 | 0 | 2 |
| HRT Versus MOS for Endometrial Preparation Prior to FET in PCOS Patients | 31.7 | 0 | 2 |
| Subcutaneous Progesterone Versus Vaginal Progesterone Gel for Luteal Phase Support | 31.7 | 0 | 2 |
| Time-lapse Monitoring of Early Embryo Development After Ovarian Stimulation During Infertility Treatment | 31.7 | 0 | 2 |
| Ovarian Stimulation and Intrauterine Insemination in Women With Polycystic Ovarian Syndrome | 31.7 | 0 | 2 |
| Comparative Assessment of the Clinical Utility of Ovarian Stimulation With Menotropin Versus Menotropin Plus GnRH Antagonist | 31.7 | 0 | 2 |
| Effect of Cervical Occlusion During Intrauterine Insemination (IUI) | 31.7 | 0 | 2 |
| Fertility Preservation in Breast Cancer Patients | 31.7 | 0 | 2 |
| Immediate Versus Delayed FET Following a Stimulated IVF Cycle | 31.7 | 0 | 2 |
| NATural Ovarian Stimulation | 31.7 | 0 | 2 |
| Mapping the Endocrine Determinants of Ovarian Stimulation to Optimize Outcomes in Fresh Embryo Transfer Cycles | 31.7 | 0 | 2 |
| Efficacy of Corifollitropin Alfa Versus Follitropin Beta in Aged IVF (In-vitro Fertilization) Patients | 31.7 | 0 | 2 |
| HRT Versus MOS for Endometrial Preparation Prior to FET in Non PCOS Patients | 31.7 | 0 | 2 |
| Intrauterine insemination after ovarian stimulation as a treatment for subfertility because of subnormal semen: a prospective randomized controlled trial | 31.7 | 0 | 2 |
| Direct intraperitoneal or intrauterine insemination and superovulation in infertility treatment: a randomized study | 31.7 | 0 | 2 |
| Outcome of in-vitro fertilization and embryo transfer after different regimens of ovarian stimulation | 31.7 | 0 | 2 |
| Differential indications for surgical technics in reproductive medicine--microsurgery, in vitro fertilization and embryo transfer, gamete intrafallopian transfer and tubal embryo transfer | 31.7 | 0 | 2 |
| Clomiphene-HMG ovarian stimulation in human in vitro fertilization and embryo transfer | 31.7 | 0 | 2 |
| In vitro fertilization and other assisted reproduction. Vth World Congress on In Vitro Fertilization and Embryo Transfer. Norfolk, Virginia, April 5-10, 1987. Proceedings | 31.7 | 0 | 2 |
| An analysis of the LH profile in relation to ovarian stimulation regimes and embryo transfer rates in an in vitro fertilisation programme | 31.7 | 0 | 2 |
| The effect of periovarian adhesions on follicular development in patients undergoing ovarian stimulation for in vitro fertilization-embryo transfer | 31.7 | 0 | 2 |
| Morphometric characteristics of endometrial biopsies after different types of ovarian stimulation for infertility treatment | 31.7 | 0 | 2 |
| The influence of sperm morphology and the number of motile sperm inseminated on the outcome of intrauterine insemination combined with mild ovarian stimulation | 31.7 | 0 | 2 |
| Gamete intra-Fallopian transfer or in-vitro fertilization after failed ovarian stimulation and intrauterine insemination in unexplained infertility? | 31.7 | 0 | 2 |
| Sonographically monitored ovarian stimulation for assisted reproduction: a prospective, blind study | 31.7 | 0 | 2 |
| Factors responsible for multiple pregnancies after ovarian stimulation and intrauterine insemination with gonadotropins | 31.7 | 0 | 2 |
| The value of intrauterine insemination in fertility treatment | 31.7 | 0 | 2 |
| Methodology of human embryo transfer following assisted reproduction | 31.7 | 0 | 2 |
| Modified hysterosalpingography catheter for embryo transfer and intrauterine insemination | 31.7 | 0 | 2 |
| The results of in vitro fertilization-embryo transfer in couples with unexplained infertility failing to conceive with superovulation and intrauterine insemination | 31.7 | 0 | 2 |
| Luteinizing hormone (LH) surge in patients using buserelin spray during ovarian stimulation for assisted reproduction | 31.7 | 0 | 2 |
| Reproductive medicine and assisted reproduction--present status and perspectives in the Czech Republic | 31.7 | 0 | 2 |
| Serum oestradiol and progesterone concentrations during prolonged coasting in 15 women at risk of ovarian hyperstimulation syndrome following ovarian stimulation for assisted reproduction treatment | 31.7 | 0 | 2 |
| Risk factors for multiple gestation in women undergoing intrauterine insemination with ovarian stimulation | 31.7 | 0 | 2 |
| Intrauterine insemination with husband's semen as alternative to other assisted reproduction techniques | 31.7 | 0 | 2 |
| A comparison of early gestational age markers in viable twin pregnancies resulting from in vitro fertilization-embryo transfer versus spontaneous conception with ovarian stimulation | 31.7 | 0 | 2 |
| Benefits and risks of ovarian stimulation before intrauterine insemination | 31.7 | 0 | 2 |
| A rational basis for antiphospholipid antibody testing and selective immunotherapy in assisted reproduction: a rebuttal to the American Society for Reproductive Medicine Practice opinion. American Society for Reproductive Immunology Antiphospholipid | 31.7 | 0 | 2 |
| The influence of infertility treatment and assisted reproduction techniques on multiple pregnancy rates | 31.7 | 0 | 2 |
| Long gonadotrophin releasing hormone agonist/human menopausal gonadotrophin protocol for ovarian stimulation in intrauterine insemination treatment | 31.7 | 0 | 2 |
| Intrauterine insemination after ovarian stimulation with clomiphene citrate: predictive potential of inseminating motile count and sperm morphology | 31.7 | 0 | 2 |
| Recombinant versus urinary FSH for ovarian stimulation in assisted reproduction | 31.7 | 0 | 2 |
| Embryo transfer: a critical step in assisted reproduction | 31.7 | 0 | 2 |
| Pregnancy after ovarian stimulation and intrauterine insemination in a woman with cavernous macrohemangioma of the liver. A case report | 31.7 | 0 | 2 |
| A case of forearm amputation after ovarian stimulation for in vitro fertilization-embryo transfer | 31.7 | 0 | 2 |
| Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation | 31.7 | 0 | 2 |
| Transfer of early-cleaved embryos increases implantation rate in patients undergoing ovarian stimulation and ICSI-embryo transfer | 31.7 | 0 | 2 |
| The Impact of Lifestyle on Sperm Telomere Length and Telomerase Activity in Men Undergoing IVF Treatments | 31.7 | 0 | 2 |
| Efficacy of superovulation and intrauterine insemination in the treatment of infertility. National Cooperative Reproductive Medicine Network | 31.7 | 0 | 2 |
| Intrauterine insemination IUI: the effect of ovarian stimulation and infertility diagnosis on pregnancy outcome | 31.7 | 0 | 2 |
| Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction | 31.7 | 0 | 2 |
| Follitropin-alfa for ovarian stimulation during assisted reproduction treatment: a national collaborative study | 31.7 | 0 | 2 |
| Blastocyst culture and transfer in clinical-assisted reproduction | 31.7 | 0 | 2 |
| Access to fertility treatment by gays, lesbians, and unmarried persons | 31.7 | 0 | 2 |
| Assessment of United States fertility clinic websites according to the American Society for Reproductive Medicine (ASRM)/Society for Assisted Reproductive Technology (SART) guidelines | 31.7 | 0 | 2 |
| [Towards a single embryo transfer: predictive value of uterine and embryological parameters in assisted reproduction outcome] | 31.7 | 0 | 2 |
| Cervical dilatation with hygroscopic rods prior to ovarian stimulation facilitates embryo transfer | 31.7 | 0 | 2 |
| Elective single embryo transfer in assisted reproduction | 31.7 | 0 | 2 |
| Health of children born after the infertility treatment with Assisted Reproduction Technology | 31.7 | 0 | 2 |
| Intrauterine insemination with controlled ovarian hyperstimulation versus expectant management for couples with unexplained subfertility and an intermediate prognosis: a randomised clinical trial | 31.7 | 0 | 2 |
| Removal of cervical mucus prior to embryo transfer improves pregnancy rates in women undergoing assisted reproduction | 31.7 | 0 | 2 |
| Role of treatment with ovarian stimulation and intrauterine insemination in women with unilateral tubal occlusion diagnosed by hysterosalpingography | 31.7 | 0 | 2 |
| Prediction of an ongoing pregnancy after intrauterine insemination | 31.7 | 0 | 2 |
| Blastocyst production and transfer in clinical assisted reproduction | 31.7 | 0 | 2 |
| Embryo splitting for infertility treatment | 31.7 | 0 | 2 |
| Assisted reproduction in male cancer survivors: fertility treatment and outcome in 67 couples | 31.7 | 0 | 2 |
| Clinical outcome with half-dose depot triptorelin is the same as reduced-dose daily buserelin in a long protocol of controlled ovarian stimulation for ICSI/embryo transfer: a randomized double-blind clinical trial (NCT00461916) | 31.7 | 0 | 2 |
| Intrauterine insemination: against systematic ovarian stimulation | 31.7 | 0 | 2 |
| Fertility treatment when the prognosis is very poor or futile | 31.7 | 0 | 2 |
| Would legislation imposing single embryo transfer be a feasible way to reduce the rate of multiple pregnancies after IVF treatment? | 31.7 | 0 | 2 |
| In vitro fertilization laboratory. Clinical features of assisted reproduction techniques. Male infertility treatment in a reproduction medicine centre | 31.7 | 0 | 2 |
| Is controlled ovarian stimulation in intrauterine insemination an acceptable therapy in couples with unexplained non-conception in the perspective of multiple pregnancies? | 31.7 | 0 | 2 |
| Elective single embryo transfer versus double embryo transfer in assisted reproduction | 31.7 | 0 | 2 |
| Single embryo transfer in IVF treatment | 31.7 | 0 | 2 |
| Recombinant gonadotrophins in reproductive medicine: gold standard for ovarian stimulation therapy in the 21st century | 31.7 | 0 | 2 |
| Guidelines for reducing the risk of viral transmission during fertility treatment | 31.7 | 0 | 2 |
| Effect of the new legislation and single-embryo transfer policy in Turkey on assisted reproduction outcomes: preliminary results | 31.7 | 0 | 2 |
| Seminal hyperviscosity is associated with poor outcome of controlled ovarian stimulation and intrauterine insemination: a prospective study | 31.7 | 0 | 2 |
| Ovarian stimulation and intrauterine insemination in women aged 40years or more | 31.7 | 0 | 2 |
| Controlled ovarian stimulation and intrauterine insemination: an actual therapy? | 31.7 | 0 | 2 |
| Comparison of the effect of two different doses of recombinant gonadotropin for ovarian stimulation on the outcome of intrauterine insemination | 31.7 | 0 | 2 |
| Laparoscopy for intrauterine insemination and embryo recovery in superovulated ewes at a commercial embryo transfer unit | 31.7 | 0 | 2 |
| Fertility treatment when the prognosis is very poor or futile: a committee opinion | 31.7 | 0 | 2 |
| Reproductive endocrinology: Infertility treatment in PCOS--is metformin in from the cold? | 31.7 | 0 | 2 |
| Results after assisted reproduction at a public fertility clinic | 31.7 | 0 | 2 |
| Recombinant FSH versus clomiphene citrate for ovarian stimulation in couples with unexplained infertility and male subfertility undergoing intrauterine insemination: a randomized trial | 31.7 | 0 | 2 |
| Strategies for hormonal ovarian stimulation in IVF, based on materials of the centre for assisted reproduction "varna" | 31.7 | 0 | 2 |
| The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomized prospective trial | 31.7 | 0 | 2 |
| Effect of different embryo transfer strategies on the outcome of assisted reproduction | 31.7 | 0 | 2 |
| Uterine contractile activity at Embryo Transfer – as a new pharmacotherapeutic target in assisted reproduction | 31.7 | 0 | 2 |
| AIUM Practice Guideline for the Performance of a Focused Reproductive Endocrinology and Infertility Scan | 31.7 | 0 | 2 |
| Fertility preservation in breast cancer patients by embryo cryopreservation after ovarian stimulation with letrozole and FSH | 31.7 | 0 | 2 |
| Comparison of pregnancy rates in PCOS patients undergoing clomiphene citrate and IUI treatment with different leading follicular sizes | 31.7 | 0 | 2 |
| A “four-cycle program” improves the estimate of the cumulative pregnancy rate and increases the number of actual pregnancies in IUI treatment: a cohort study | 31.7 | 0 | 2 |
| Successful pregnancy following assisted reproduction and transmyometrial embryo transfer in a patient with anatomical distortion of the cervical canal | 31.7 | 0 | 2 |
| Ovarian stimulation in infertile women treated with the use of intrauterine insemination: a cohort study from China | 31.7 | 0 | 2 |
| Comparison of pregnancy rates for poor responders using IVF with mild ovarian stimulation versus conventional IVF: a guideline | 31.7 | 0 | 2 |
| Dose-finding study of Leuplin depot for prevention of premature luteinizing hormone surge during controlled ovarian stimulation: a pilot study in intrauterine insemination treatment | 31.7 | 0 | 2 |
| ASRM standard embryo transfer protocol template: a committee opinion | 31.7 | 0 | 2 |
| Compassionate transfer: patient requests for embryo transfer for nonreproductive purposes | 31.7 | 0 | 2 |
| Use of exogenous gonadotropins for ovulation induction in anovulatory women: a committee opinion | 31.7 | 0 | 2 |
| Timing of frozen-thawed embryo transfer after controlled ovarian stimulation in a non-elective freeze-all policy | 31.7 | 0 | 2 |
| Effects of letrozole combined with human menopausal gonadotrophin in ovarian stimulation for intrauterine insemination cycles | 31.7 | 0 | 2 |
| Current Preventive Strategies for Preovulatory Progesterone Elevation During Ovarian Stimulation for In Vitro Fertilization | 31.7 | 0 | 2 |
| Outcomes of fertility preservation in women with endometriosis: comparison of progestin-primed ovarian stimulation versus antagonist protocols | 31.7 | 0 | 2 |
| The effect of follicular phase length on cycle outcomes and endometrial development in gonadotrophin ovarian stimulation/intrauterine insemination cycles | 31.7 | 0 | 2 |
| The effect of fresh IVF cycle characteristics on frozen embryo transfer (FET) outcomes | 31.7 | 0 | 2 |
| Predictors of twin pregnancy after ovarian stimulation and intrauterine insemination in women with unexplained infertility | 31.7 | 0 | 2 |
| Live birth rate comparison of three controlled ovarian stimulation protocols for in vitro fertilization-embryo transfer in patients with diminished ovarian reserve after endometrioma cystectomy: a retrospective study | 31.7 | 0 | 2 |
| Blastocyst culture and transfer in clinically assisted reproduction: a committee opinion | 31.7 | 0 | 2 |
| Ovarian stimulation for fertility preservation in women diagnosed with cancer | 31.7 | 0 | 2 |
| The impact of malignancy on response to ovarian stimulation for fertility preservation: a meta-analysis | 31.7 | 0 | 2 |
| Outcomes of ovarian stimulation and fertility preservation in breast cancer patients with different hormonal receptor profiles | 31.7 | 0 | 2 |
| Fertility Preservation: Improving Access Through Nurse-Advocated Financial Assistance | 31.7 | 0 | 2 |
| Elective Single Embryo Transfer in the Setting of Funded In Vitro Fertilization: Two Years' Experience in an Ontario Hospital-Based Fertility Clinic | 31.7 | 0 | 2 |
| Curative effect of assisted reproduction technology by Traditional Chinese Medicine multi-channel interventional therapy on 95 cases of in vitro fertilization and embryo transfer failure | 31.7 | 0 | 2 |
| Androgenicity and fertility treatment in women with unexplained infertility | 31.7 | 0 | 2 |
| The effects of intrauterine insemination and single embryo transfer or modified natural cycle in vitro fertilization on offspring's health-Follow-up of a randomized clinical trial | 31.7 | 0 | 2 |
| The effect of female age on the outcome of intrauterine insemination treatment in a public hospital-assisted reproduction technology unit | 31.7 | 0 | 2 |
| Evaluating the benefit of measuring serum progesterone prior to the administration of HCG: effect of the duration of late-follicular elevated progesterone following ovarian stimulation on fresh embryo transfer live birth rates | 31.7 | 0 | 2 |
| Vitamin D Deficiency Is Associated With Poor Ovarian Stimulation Outcome in PCOS but Not Unexplained Infertility | 31.7 | 0 | 2 |
| Prospective randomized trial comparing efficacy of letrozole step-up protocol with letrozole plus gonadotropins for controlled ovarian stimulation and intrauterine insemination in patients with unexplained infertility | 31.7 | 0 | 2 |
| Luteal-phase progesterone supplementation in non-IVF treatment: a survey of physicians providing infertility treatment | 31.7 | 0 | 2 |
| Impact of letrozole supplementation during ovarian stimulation for fertility preservation in breast cancer patients | 31.7 | 0 | 2 |
| Oocyte exposure to supraphysiological estradiol during ovarian stimulation increased the risk of adverse perinatal outcomes after frozen-thawed embryo transfer: a retrospective cohort study | 31.7 | 0 | 2 |
| Influence of surgical evacuation on pregnancy outcomes of subsequent embryo transfer cycle following miscarriage in an initial IVF cycle: a retrospective cohort study | 31.7 | 0 | 2 |
| Effects of cancer stage and grade on fertility preservation outcome and ovarian stimulation response | 31.7 | 0 | 2 |
| Vaginal cuff dehiscence following controlled ovarian stimulation recognized during egg retrieval | 31.7 | 0 | 2 |
| Defining thresholds for abnormal premature progesterone levels during ovarian stimulation for assisted reproduction technologies | 31.7 | 0 | 2 |
| Abstracts presented at the 2019 Foundation for Reproductive Medicine Conference on Translational Reproductive Biology and Clinical Reproductive Endocrinology | 31.7 | 0 | 2 |
| The ethics of fertility treatment for same-sex male couples: Considerations for a modern fertility clinic | 31.7 | 0 | 2 |
| [Medically Assisted Reproduction in Natural Cycle: Outcome Evaluation of a Reproductive Medicine Department] | 31.7 | 0 | 2 |
| Corticosteroids Prior to Embryo Transfer in Assisted Reproduction in Women with Crohn's Disease and Ulcerative Colitis - A Nationwide Cohort Study | 31.7 | 0 | 2 |
| Predictive factors for pregnancy after controlled ovarian stimulation and intrauterine insemination: A retrospective analysis of 4146 cycles | 31.7 | 0 | 2 |
| Mature Follicle Count and Multiple Gestation Risk Based on Patient Age in Intrauterine Insemination Cycles With Ovarian Stimulation | 31.7 | 0 | 2 |
| Financial Assistance for Fertility Preservation Among Adolescent and Young Adult Cancer Patients: A Utilization Review of the Sharing Hope/LIVESTRONG Fertility Financial Assistance Program | 31.7 | 0 | 2 |
| Risk factors for inadequate response to ovarian stimulation in assisted reproduction cycles: systematic review | 31.7 | 0 | 2 |
| Ovarian stimulation is a safe and effective fertility preservation option in the adolescent and young adult population | 31.7 | 0 | 2 |
| Conservative treatment versus surgical excision of ovarian dermoid cysts: Impact on ovarian stimulation and IVF cycle success | 31.7 | 0 | 2 |
| The effect of a natural vaginal product based on honey on the success of intrauterine insemination (IUI) in infertility treatment | 31.7 | 0 | 2 |
| Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion | 31.7 | 0 | 2 |
| EUropean REcommendations for female FERtility preservation (EU-REFER): A joint collaboration between oncologists and fertility specialists | 31.7 | 0 | 2 |
| Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer-a prospective nationwide Swedish multicenter study | 31.7 | 0 | 2 |
| Use of Frozen Embryo Transfer During Fertility Treatment and Risk of Childhood Cancer | 31.7 | 0 | 2 |
| Use of Frozen Embryo Transfer During Fertility Treatment and Risk of Childhood Cancer-Reply | 31.7 | 0 | 2 |
| Isthmocele and ovarian stimulation for IVF: considerations for a reproductive medicine specialist | 31.7 | 0 | 2 |
| Fertility treatment when the prognosis is very poor or futile: an Ethics Committee opinion | 31.7 | 0 | 2 |
| Ovarian stimulation and egg retrieval in the acutely ill patient: special considerations | 31.7 | 0 | 2 |
| Endometrial thickness on the day of embryo transfer is a poor predictor of IVF treatment outcome | 31.7 | 0 | 2 |
| Elective egg freezing and male support: a qualitative study of men's roles in women's fertility preservation | 31.7 | 0 | 2 |
| Analysis of embryo quality with luteal phase ovarian stimulation after failed in vitro fertilization-embryo transfer with long or ultra-long protocol | 31.7 | 0 | 2 |
| Gonadotropin releasing hormone antagonist use in controlled ovarian stimulation and intrauterine insemination cycles in women with polycystic ovary syndrome | 31.7 | 0 | 2 |
| Ovarian stimulation for fertility preservation or family building in a cohort of transgender men | 31.7 | 0 | 2 |
| The Impact of Traditional Medicine-Based Lifestyle and Diet on Infertility Treatment in Women Undergoing Assisted Reproduction: A Randomized Controlled Trial | 31.7 | 0 | 2 |
| Transvaginal ovarian drilling followed by controlled ovarian stimulation from the next day improves ovarian response for the poor responders with polycystic ovary syndrome during IVF treatment: a pilot study | 31.7 | 0 | 2 |
| Evaluation of the effect of the elective blastocyst-stage embryo transfer and freezing strategy on the abandonment of frozen embryos under the Taiwan National Assisted Reproduction Act | 31.7 | 0 | 2 |
| Patient perceptions and understanding of treatment instructions for ovarian stimulation during infertility treatment | 31.7 | 0 | 2 |
| Follicle stimulating hormone or clomiphene citrate in intrauterine insemination with ovarian stimulation for unexplained subfertility: a role for treatment selection markers? | 31.7 | 0 | 2 |
| Association between testosterone, semen parameters, and live birth in men with unexplained infertility in an intrauterine insemination population | 31.7 | 0 | 2 |
| A Randomized Trial Comparing the Live Birth Rate of Immediate Versus Delayed Frozen Embryo Transfer (FET) Following a Freeze-all Strategy | 31.7 | 0 | 2 |
| [Elective single embryo transfer in assisted reproduction] | 31.7 | 0 | 2 |
| When is the optimal timing of frozen embryo transfer after controlled ovarian stimulation? | 31.7 | 0 | 2 |
| Intrauterine insemination performance characteristics and post-processing total motile sperm count in relation to live birth for couples with unexplained infertility in a randomised, multicentre clinical trial | 31.7 | 0 | 2 |
| Changes in the levels of selected metabolites in the culture medium as a possible tool for the embryo selection in assisted reproduction | 31.7 | 0 | 2 |
| Effect of triple line vs isoechogenic endometrial texture on pregnancy outcome following embryo transfer according to use of controlled ovarian stimulation (COH) or estrogen/progesterone replacement | 31.7 | 0 | 2 |
| Attitudes and experiences of health care professionals when caring for transgender men undergoing fertility preservation by egg freezing: a qualitative study | 31.7 | 0 | 2 |
| How fixed versus variable gonadotropin dose during controlled ovarian stimulation could influence the management of infertility patients undergoing IVF treatment: a national Delphi consensus | 31.7 | 0 | 2 |
| Aneuploid embryo transfer: clinical policies and provider opinions at United States fertility clinics | 31.7 | 0 | 2 |
| Importance of early and precise ascertainment of mosaic Turner syndrome for fertility preservation and assisted reproduction counseling | 31.7 | 0 | 2 |
| IVM Survey Among Reproductive Medicine Specialists | 31.7 | 0 | 2 |
| Ng Soon Chye | 31.7 | 0 | 2 |
| Further evidence that a supraphysiologic estradiol level during ovarian stimulation affects birthweight: findings of fresh and frozen embryo transfer with comparable estradiol levels on human chorionic gonadotropin trigger | 31.7 | 0 | 2 |
| Endometrial thickness after ovarian stimulation with gonadotropin, clomiphene, or letrozole for unexplained infertility, and association with treatment outcomes | 31.7 | 0 | 2 |
| Early Progesterone Change Associated With Pregnancy Outcome After Fresh Embryo Transfer in Assisted Reproduction Technology Cycles With Progesterone Level of >1.5 ng/ml on Human Chorionic Gonadotropin Trigger Day | 31.7 | 0 | 2 |
| Gender-specific aspects related to type of fertility preservation strategies and access to fertility care | 31.7 | 0 | 2 |
| Efficacy and Safety of Controlled Ovarian Stimulation With or Without Letrozole Co-administration for Fertility Preservation: A Systematic Review and Meta-Analysis | 31.7 | 0 | 2 |
| Double-in vitro maturation increases the number of vitrified oocytes available for fertility preservation when ovarian stimulation is unfeasible | 31.7 | 0 | 2 |
| Is intrauterine insemination a viable treatment option for women over 43 years old? An analysis by ovarian stimulation protocol and sperm source | 31.7 | 0 | 2 |
| Should couples with unexplained infertility have three to six cycles of intrauterine insemination with ovarian stimulation or in vitro fertilization as first-line treatment? | 31.7 | 0 | 2 |
| Recommendations for reducing the risk of viral transmission during fertility treatment with the use of autologous gametes: a committee opinion | 31.7 | 0 | 2 |
| The marketing of elective egg freezing: A content, cost and quality analysis of UK fertility clinic websites | 31.7 | 0 | 2 |
| Outcome of mock embryo transfer before the first IVF cycle: A randomized control trial | 31.7 | 0 | 2 |
| Simulation training for embryo transfer: findings from the American Society for Reproductive Medicine Embryo Transfer Certificate Course | 31.7 | 0 | 2 |
| Experiences of women undergoing infertility treatment from embryo transfer until pregnancy test and their conceptualization of their embryo | 31.7 | 0 | 2 |
| Mandated Health Insurance Benefits and the Utilization and Outcomes of Infertility Treatments | 31.7 | 0 | 2 |
| An in silico model using prognostic genetic factors for ovarian response in controlled ovarian stimulation: A systematic review | 31.7 | 0 | 2 |
| A Federated Blockchain Approach for Fertility Preservation and Assisted Reproduction in Smart Cities | 31.7 | 0 | 2 |
| Is letrozole during ovarian stimulation useful in breast cancer patients undergoing fertility preservation to reduce early luteal progesterone levels following GnRH-agonist trigger? | 31.7 | 0 | 2 |
| Women’s preferences concerning IVF treatment: a discrete choice experiment with particular focus on embryo transfer policy | 31.7 | 0 | 2 |
| Efficacy and Safety of Fertility Treatments and Fertility Preservation | 31.7 | 0 | 2 |
| Analysis of the Composition of the Vaginal Microbiota During IVF Treatment and Correlation With Serum Progesterone Level on the Day of Embryo Transfer | 31.7 | 0 | 2 |
| The Inferto-Sex Syndrome (ISS): sexual dysfunction in fertility care setting and assisted reproduction | 31.7 | 0 | 2 |
| Pregnancy Rate (PR) With In-Vitro Fertilization (IVF) When the Egg Retrieval (ER) and the Embryo Transfer (ET) are Done by the Same Physician or by Different Physicians | 31.7 | 0 | 2 |
| Towards personalised reproductive medicine: screening for genetic variants and its influence in controlled ovarian stimulation | 31.7 | 0 | 2 |
| Gonadotropin-specific follicular steroidogenesis in ovarian stimulation: evidence from the menopur in GnRH antagonist single embryo transfer - high responder (MEGASET-HR) trial | 31.7 | 0 | 2 |
| Elective egg freezing and male support: a qualitative study of men’s hidden roles in women’s fertility preservation | 31.7 | 0 | 2 |
| Risk of ectopic pregnancy after different ovarian stimulation protocols in fresh single embryo transfer: analysis of 71,831 cycles from the Japanese ART registry | 31.7 | 0 | 2 |
| SINGLE VERSUS DOUBLE INTRAUTERINE INSEMINATION IN CONTROLLED OVARIAN STIMULATION CYCLES FOR SUBFERTILE MALES | 31.7 | 0 | 2 |
| Selective Discontinuation of Luteal Phase Support in Assisted Reproduction Cycles Using a Gonadotropin-Releasing Hormone Agonist and Human Menopausal Gonadotropins for Ovarian Stimulation | 31.7 | 0 | 2 |
| Association between the number of oocytes retrieved and cumulative live birth rate in IVF treatment: menopur in GnRH antagonist single embryo transfer - high responder (MEGASET-HR) trial outcomes | 31.7 | 0 | 2 |
| Letrozole Ovarian Stimulation improves Outcome of Endometrial Scratching prior to Intrauterine Insemination Procedure | 31.7 | 0 | 2 |
| Recent Advances in Reproductive Endocrinology: Implications for Fertility Treatment in Gynecology | 31.7 | 0 | 2 |
| What are the benefits and harms of intrauterine administration of human chorionic gonadotropin (hCG) around the time of embryo transfer for subfertile women undergoing assisted reproduction? | 31.7 | 0 | 2 |
| Recombinant FSH dosing during controlled ovarian stimulation in IVF treatment | 31.7 | 0 | 2 |
| Impact of the Duration of Controlled Ovarian Stimulation on Assisted Reproduction Cycle Outcomes | 31.7 | 0 | 2 |
| Obstetric and Perinatal Outcomes of Pregnancies After Infertility Treatment Using Assisted Reproductive Technologies With Cryopreserved Embryo Transfer | 31.7 | 0 | 2 |
| Singletons birthweight after frozen-thawed embryo transfer is increased after endometrial preparation with artificial cycle compared to mild gonadotropin ovarian stimulation | 31.7 | 0 | 2 |
| Ovarian stimulation is a safe and effective fertility preservation (FP) option in the adolescent population | 31.7 | 0 | 2 |
| Egg freezing for fertility preservation and family planning: a survey of OB/GYN residents across united states | 31.7 | 0 | 2 |
| Random start versus conventional start controlled ovarian stimulation in women with cancer: comparing oocyte yield among fertility preservation cycles | 31.7 | 0 | 2 |
| Anti-mullerian hormone level as a predictor of ovarian reserve in patients seeking fertility preservation versus infertility treatment | 31.7 | 0 | 2 |
| impact of breast cancer prognostic factors on the response to controlled ovarian stimulation patients undergoing fertility preservation | 31.7 | 0 | 2 |
| How does freeze-all strategy compare with conventional in vitro fertilization and fresh embryo transfer during assisted reproduction? | 31.7 | 0 | 2 |
| Q137191222 | 31.7 | 0 | 2 |
| Cyprus Fertina IVF Clinic | 31.7 | 0 | 2 |
| ADVFN | 30.0 | 1 | 0 |
| PR Newswire | 30.0 | 1 | 0 |
| United States Centers for Disease Control and Prevention | 30.0 | 1 | 0 |
| CVS Health | 30.0 | 1 | 0 |
| ResearchGate | 30.0 | 1 | 0 |
| Bowdoin College | 30.0 | 1 | 0 |
| Q1023911 | 30.0 | 1 | 0 |
| CNBC | 30.0 | 1 | 0 |
| CRH | 30.0 | 1 | 0 |
| University of California, San Francisco | 30.0 | 1 | 0 |
| Pennsylvania Hospital | 30.0 | 1 | 0 |
| Morbidity and Mortality Weekly Report | 30.0 | 1 | 0 |
| Squawk Box | 30.0 | 1 | 0 |
| Maine Legislature | 30.0 | 1 | 0 |
| Arkivoc | 30.0 | 1 | 0 |
| cinema of Bangladesh | 30.0 | 1 | 0 |
| National Center for Health Statistics | 30.0 | 1 | 0 |
| Worldwide Exchange | 30.0 | 1 | 0 |
| Squawk on the Street | 30.0 | 1 | 0 |
| Power Lunch | 30.0 | 1 | 0 |
| Closing Bell | 30.0 | 1 | 0 |
| Q4261093 | 30.0 | 1 | 0 |
| Advisory Committee on Immunization Practices | 30.0 | 1 | 0 |
| American Greed | 30.0 | 1 | 0 |
| Anne Schuchat | 30.0 | 1 | 0 |
| BabyCenter | 30.0 | 1 | 0 |
| Bowdoin College Museum of Art | 30.0 | 1 | 0 |
| Capital Connection | 30.0 | 1 | 0 |
| David Faber | 30.0 | 1 | 0 |
| Emerging Infectious Diseases | 30.0 | 1 | 0 |
| Epi Map | 30.0 | 1 | 0 |
| Epidemic Intelligence Service | 30.0 | 1 | 0 |
| Families USA | 30.0 | 1 | 0 |
| Fast Money | 30.0 | 1 | 0 |
| Fire Fighter Fatality Investigation and Prevention Program | 30.0 | 1 | 0 |
| Foreign Exchange | 30.0 | 1 | 0 |
| Health Hazard Evaluation | 30.0 | 1 | 0 |
| Hospital of the University of Pennsylvania | 30.0 | 1 | 0 |
| Johnnie B. Byrd, Sr. Alzheimer's Center & Research Institute | 30.0 | 1 | 0 |
| Mad Money | 30.0 | 1 | 0 |
| Man in India | 30.0 | 1 | 0 |
| NYU Langone Health | 30.0 | 1 | 0 |
| National Center for Injury Prevention and Control | 30.0 | 1 | 0 |
| National Diabetes Education Program | 30.0 | 1 | 0 |
| National Health Interview Survey | 30.0 | 1 | 0 |
| On the Money | 30.0 | 1 | 0 |
| Peary–MacMillan Arctic Museum | 30.0 | 1 | 0 |
| Penn Presbyterian Medical Center | 30.0 | 1 | 0 |
| Perelman Center for Advanced Medicine | 30.0 | 1 | 0 |
| Public Health Information Network | 30.0 | 1 | 0 |
| Scheie Eye Institute | 30.0 | 1 | 0 |
| Stanford Hospital and Clinics | 30.0 | 1 | 0 |
| Stanford University Medical Center | 30.0 | 1 | 0 |
| Street Signs | 30.0 | 1 | 0 |
| Stripe | 30.0 | 1 | 0 |
| The Kudlow Report | 30.0 | 1 | 0 |
| On the Money | 30.0 | 1 | 0 |
| Trash Inc: The Secret Life of Garbage | 30.0 | 1 | 0 |
| University of Pennsylvania Health System | 30.0 | 1 | 0 |
| University of South Florida College of Medicine | 30.0 | 1 | 0 |
| University of South Florida College of Nursing | 30.0 | 1 | 0 |
| University of South Florida College of Public Health | 30.0 | 1 | 0 |
| VERB | 30.0 | 1 | 0 |
| Vaccines for Children Program | 30.0 | 1 | 0 |
| NIOSH World Trade Center Health Program | 30.0 | 1 | 0 |
| Morning Call | 30.0 | 1 | 0 |
| National Death Index | 30.0 | 1 | 0 |
| National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention | 30.0 | 1 | 0 |
| Office of Women's Health | 30.0 | 1 | 0 |
| National Center for Immunization and Respiratory Diseases | 30.0 | 1 | 0 |
| Secret Lives of the Super Rich | 30.0 | 1 | 0 |
| NIOSH pocket guide to chemical hazards (superseded) | 30.0 | 1 | 0 |
| West Texas Investors Club | 30.0 | 1 | 0 |
| Helena Foulkes | 30.0 | 1 | 0 |
| Q21531806 | 30.0 | 1 | 0 |
| National Violent Death Reporting System | 30.0 | 1 | 0 |
| Sonja A. Rasmussen | 30.0 | 1 | 0 |
| Monthly vital statistics report : provisional statistics from the National Center for Health Statistics | 30.0 | 1 | 0 |
| Advance data | 30.0 | 1 | 0 |
| Frontiers of biology | 30.0 | 1 | 0 |
| Hellenis adelphe | 30.0 | 1 | 0 |
| Vital and health statistics. Series 10, Data from the National Health Survey | 30.0 | 1 | 0 |
| Vital and health statistics. Series 11, Data from the national health survey | 30.0 | 1 | 0 |
| Vital and health statistics. Series 21, Data from the National Vital Statistics System | 30.0 | 1 | 0 |
| Vital and health statistics. Series 23, Data from the National Survey of Family Growth | 30.0 | 1 | 0 |
| Vital and health statistics. Series 20, Data from the National Vital Statistics System | 30.0 | 1 | 0 |
| National health statistics reports | 30.0 | 1 | 0 |
| Systems Biology in Reproductive Medicine | 20.0 | 0 | 1 |
| Robert Edwards | 20.0 | 0 | 1 |
| target costing | 20.0 | 0 | 1 |
| Gigi Fernández | 20.0 | 0 | 1 |
| embryo transfer | 20.0 | 0 | 1 |
| whole-life cost | 20.0 | 0 | 1 |
| reproductive medicine | 20.0 | 0 | 1 |
| integrated logistics support | 20.0 | 0 | 1 |
| egg donation | 20.0 | 0 | 1 |
| Municipal Transport Financing Act | 20.0 | 0 | 1 |
| Student Financial Assistance | 20.0 | 0 | 1 |
| Creighton Model FertilityCare System | 20.0 | 0 | 1 |
| Community Assistance for Reconstruction, Development, and Stabilisation | 20.0 | 0 | 1 |
| Vitrification (ovocytes) | 20.0 | 0 | 1 |
| patronat | 20.0 | 0 | 1 |
| Casa Inc. | 20.0 | 0 | 1 |
| Center for Reproductive Medicine | 20.0 | 0 | 1 |
| Greater Washington Community Foundation | 20.0 | 0 | 1 |
| Copyright, Designs and Patents Act 1988 | 20.0 | 0 | 1 |
| Electricity Act 1989 | 20.0 | 0 | 1 |
| Endocrinology of reproduction | 20.0 | 0 | 1 |
| Enhanced structural adjustment facility | 20.0 | 0 | 1 |
| fertility preservation | 20.0 | 0 | 1 |
| fertility tourism | 20.0 | 0 | 1 |
| Financial Assistance Scheme | 20.0 | 0 | 1 |
| Financial assistance | 20.0 | 0 | 1 |
| financial assistance | 20.0 | 0 | 1 |
| Financial assistance following the September 11 attacks | 20.0 | 0 | 1 |
| Fisheries Act 1981 | 20.0 | 0 | 1 |
| Human Fertilisation and Embryology (Deceased Fathers) Act 2003 | 20.0 | 0 | 1 |
| Industrial Development (Financial Assistance) Act 2003 | 20.0 | 0 | 1 |
| student financial aid | 20.0 | 0 | 1 |
| life-cycle cost analysis | 20.0 | 0 | 1 |
| Local Government Act 1988 | 20.0 | 0 | 1 |
| Merchant Shipping Act 1988 | 20.0 | 0 | 1 |
| Money Back Guarantee | 20.0 | 0 | 1 |
| National Social Assistance Scheme | 20.0 | 0 | 1 |
| Northern Ireland (Monitoring Commission etc.) Act 2003 | 20.0 | 0 | 1 |
| Ovarian hyperstimulation | 20.0 | 0 | 1 |
| Ovarian stimulation | 20.0 | 0 | 1 |
| Reproductive endocrinology | 20.0 | 0 | 1 |
| reproductive surgery | 20.0 | 0 | 1 |
| Retirement Insurance Benefits | 20.0 | 0 | 1 |
| semen collection | 20.0 | 0 | 1 |
| Shared Risk Resource Group | 20.0 | 0 | 1 |
| Slovenian fertility treatment referendum, 2001 | 20.0 | 0 | 1 |
| Special Program of Assisted Reproduction | 20.0 | 0 | 1 |
| third-party reproduction | 20.0 | 0 | 1 |
| Category:A-Class reproductive medicine articles | 20.0 | 0 | 1 |
| Category:B-Class reproductive medicine articles | 20.0 | 0 | 1 |
| Category:C-Class reproductive medicine articles | 20.0 | 0 | 1 |
| Category:FA-Class reproductive medicine articles | 20.0 | 0 | 1 |
| Category:FL-Class reproductive medicine articles | 20.0 | 0 | 1 |
| Category:GA-Class reproductive medicine articles | 20.0 | 0 | 1 |
| Category:High-importance reproductive medicine articles | 20.0 | 0 | 1 |
| Category:Low-importance reproductive medicine articles | 20.0 | 0 | 1 |
| Category:Mid-importance reproductive medicine articles | 20.0 | 0 | 1 |
| Category:Reproductive medicine articles by importance | 20.0 | 0 | 1 |
| Category:Reproductive medicine articles by quality | 20.0 | 0 | 1 |
| Category:Reproductive medicine task force | 20.0 | 0 | 1 |
| Category:Reproductive medicine task force articles | 20.0 | 0 | 1 |
| Category:NA-Class reproductive medicine pages | 20.0 | 0 | 1 |
| Category:NA-importance reproductive medicine pages | 20.0 | 0 | 1 |
| Category:Start-Class reproductive medicine articles | 20.0 | 0 | 1 |
| Category:Stub-Class reproductive medicine articles | 20.0 | 0 | 1 |
| Category:Top-importance reproductive medicine articles | 20.0 | 0 | 1 |
| Category:Unassessed reproductive medicine articles | 20.0 | 0 | 1 |
| Category:Unknown-importance reproductive medicine articles | 20.0 | 0 | 1 |
| public assistance | 20.0 | 0 | 1 |
| financial counseling | 20.0 | 0 | 1 |
| First Economic Adjustment Programme for Greece | 20.0 | 0 | 1 |
| Category:List-Class reproductive medicine articles | 20.0 | 0 | 1 |
| intrauterine insemination | 20.0 | 0 | 1 |
| Seminars in Reproductive Medicine | 20.0 | 0 | 1 |
| Molecular Human Reproduction | 20.0 | 0 | 1 |
| Journal of Reproductive Medicine | 20.0 | 0 | 1 |
| Obstetrics, Gynaecology and Reproductive Medicine | 20.0 | 0 | 1 |
| Anna Glasier | 20.0 | 0 | 1 |
| Partner-assisted reproduction | 20.0 | 0 | 1 |
| Disaster Financial Assistance Arrangements | 20.0 | 0 | 1 |
| Help to Buy | 20.0 | 0 | 1 |
| reproductive endocrinology and infertility | 20.0 | 0 | 1 |
| New Zealand government denies financial assistance for Overlander | 20.0 | 0 | 1 |
| Australian government announces $52.5 million financial assistance package for Ford | 20.0 | 0 | 1 |
| Working Family and Student Financial Assistance Agency | 20.0 | 0 | 1 |
| Template:Clist financial assistance | 20.0 | 0 | 1 |
| Ectopic pregnancy secondary to in vitro fertilisation-embryo transfer: pathogenic mechanisms and management strategies | 20.0 | 0 | 1 |
| Reproductive medicine in northwest Argentina: traditional and institutional systems | 20.0 | 0 | 1 |
| Financial Assistance Programme for Spain | 20.0 | 0 | 1 |
| WikiProject Reproductive medicine | 20.0 | 0 | 1 |
| cost breakdown analysis | 20.0 | 0 | 1 |
| Consensus on infertility treatment related to polycystic ovary syndrome | 20.0 | 0 | 1 |
| Clomiphene, Metformin, or Both for Infertility in the Polycystic Ovary Syndrome | 20.0 | 0 | 1 |
| Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group | 20.0 | 0 | 1 |
| An historical look at embryo transfer | 20.0 | 0 | 1 |
| Peter C. Klatsky | 20.0 | 0 | 1 |
| Naprotechnology | 20.0 | 0 | 1 |
| The association of bisphenol-A urinary concentrations with antral follicle counts and other measures of ovarian reserve in women undergoing infertility treatments | 20.0 | 0 | 1 |
| Interactions of sperm perinuclear theca with the oocyte: implications for oocyte activation, anti-polyspermy defense, and assisted reproduction | 20.0 | 0 | 1 |
| Intrauterine administration of human chorionic gonadotropin (hCG) for subfertile women undergoing assisted reproduction | 20.0 | 0 | 1 |
| Temperature of embryo culture for assisted reproduction | 20.0 | 0 | 1 |
| Ultrasound versus 'clinical touch' for catheter guidance during embryo transfer in women | 20.0 | 0 | 1 |
| Long-acting FSH versus daily FSH for women undergoing assisted reproduction | 20.0 | 0 | 1 |
| Luteal phase support for assisted reproduction cycles | 20.0 | 0 | 1 |
| Application of seminal plasma to female genital tract prior to embryo transfer in assisted reproductive technology cycles (IVF, ICSI and frozen embryo transfer) | 20.0 | 0 | 1 |
| Synchronised approach for intrauterine insemination in subfertile couples | 20.0 | 0 | 1 |
| Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction | 20.0 | 0 | 1 |
| Endometrial injury for pregnancy following sexual intercourse or intrauterine insemination | 20.0 | 0 | 1 |
| Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction | 20.0 | 0 | 1 |
| Time-lapse systems for embryo incubation and assessment in assisted reproduction | 20.0 | 0 | 1 |
| Intrauterine administration of human chorionic gonadotropin (hCG) for subfertile women undergoing assisted reproduction | 20.0 | 0 | 1 |
| Advanced sperm selection techniques for assisted reproduction | 20.0 | 0 | 1 |
| Vasodilators for women undergoing fertility treatment | 20.0 | 0 | 1 |
| Time-lapse systems for embryo incubation in assisted reproduction | 20.0 | 0 | 1 |
| Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI) | 20.0 | 0 | 1 |
| Conservative treatments in gynaecological cancer for fertility preservation | 20.0 | 0 | 1 |
| Fresh versus frozen embryo transfers for assisted reproduction | 20.0 | 0 | 1 |
| In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction | 20.0 | 0 | 1 |
| Tamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction | 20.0 | 0 | 1 |
| Regular (ICSI) versus ultra-high magnification (IMSI) sperm selection for assisted reproduction | 20.0 | 0 | 1 |
| Adherence compounds in embryo transfer media for assisted reproductive technologies | 20.0 | 0 | 1 |
| Advanced sperm selection techniques for assisted reproduction | 20.0 | 0 | 1 |
| Heparin for assisted reproduction | 20.0 | 0 | 1 |
| Antibiotics prior to embryo transfer in ART | 20.0 | 0 | 1 |
| Regular (ICSI) versus ultra-high magnification (IMSI) sperm selection for assisted reproduction | 20.0 | 0 | 1 |
| Depot versus daily administration of gonadotrophin-releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles | 20.0 | 0 | 1 |
| Androgens (dehydroepiandrosterone or testosterone) in women undergoing assisted reproduction | 20.0 | 0 | 1 |
| Pain relief for women undergoing oocyte retrieval for assisted reproduction | 20.0 | 0 | 1 |
| Cleavage stage versus blastocyst stage embryo transfer in assisted reproductive technology | 20.0 | 0 | 1 |
| Vasodilators for women undergoing assisted reproduction | 20.0 | 0 | 1 |
| Tamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction | 20.0 | 0 | 1 |
| Long-acting FSH versus daily FSH for women undergoing assisted reproduction | 20.0 | 0 | 1 |
| Intrauterine insemination versus fallopian tube sperm perfusion for non-tubal infertility | 20.0 | 0 | 1 |
| Clomiphene citrate in combination with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilization | 20.0 | 0 | 1 |
| Long-acting FSH versus daily FSH for women undergoing assisted reproduction | 20.0 | 0 | 1 |
| Immune therapies for women with history of failed implantation undergoing IVF treatment | 20.0 | 0 | 1 |
| Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles | 20.0 | 0 | 1 |
| Luteal phase support for assisted reproduction cycles | 20.0 | 0 | 1 |
| Adherence compounds in embryo transfer media for assisted reproductive technologies | 20.0 | 0 | 1 |
| Antibiotics prior to embryo transfer in ART | 20.0 | 0 | 1 |
| Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction | 20.0 | 0 | 1 |
| Clomiphene citrate for controlled ovarian stimulation in women undergoing in vitro fertilization | 20.0 | 0 | 1 |
| Heparin for assisted reproduction | 20.0 | 0 | 1 |
| Human chorionic gonadotrophin priming for fertility treatment with in vitro maturation | 20.0 | 0 | 1 |
| Synchronised approach for intrauterine insemination in subfertile couples | 20.0 | 0 | 1 |
| Luteal phase support for assisted reproduction cycles | 20.0 | 0 | 1 |
| Soft versus firm catheters for intrauterine insemination | 20.0 | 0 | 1 |
| Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles | 20.0 | 0 | 1 |
| Conservative treatments in gynaecological cancer for fertility preservation | 20.0 | 0 | 1 |
| Techniques for preparation prior to embryo transfer | 20.0 | 0 | 1 |
| Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques | 20.0 | 0 | 1 |
| Techniques for preparation prior to embryo transfer | 20.0 | 0 | 1 |
| Post-embryo transfer interventions for in vitro fertilization and intracytoplasmic sperm injection patients | 20.0 | 0 | 1 |
| Ultrasound versus 'clinical touch' for catheter guidance during embryo transfer in women | 20.0 | 0 | 1 |
| Endometrial preparation for women undergoing embryo transfer with frozen embryos or embryos derived from donor oocytes | 20.0 | 0 | 1 |
| In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction | 20.0 | 0 | 1 |
| Hyaluronic Acid inclusion in embryo transfer media for assisted reproductive technologies | 20.0 | 0 | 1 |
| Luteal phase support in assisted reproduction cycles | 20.0 | 0 | 1 |
| Cycle regimens for frozen-thawed embryo transfer | 20.0 | 0 | 1 |
| Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI) | 20.0 | 0 | 1 |
| Ultrasound versus 'clinical touch' for catheter guidance during embryo transfer in women | 20.0 | 0 | 1 |
| Semen preparation techniques for intrauterine insemination | 20.0 | 0 | 1 |
| Timing modalities for intrauterine insemination in subfertile couples | 20.0 | 0 | 1 |
| Cleavage stage versus blastocyst stage embryo transfer in assisted reproductive technology | 20.0 | 0 | 1 |
| Endometrial preparation for women undergoing embryo transfer with frozen embryos or embryos derived from donor oocytes | 20.0 | 0 | 1 |
| Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI) | 20.0 | 0 | 1 |
| Soft versus firm catheters for intrauterine insemination | 20.0 | 0 | 1 |
| In vitro maturation in sub fertile patients with polycystic ovarian syndrome undergoing assisted reproduction | 20.0 | 0 | 1 |
| Depot versus daily administration of gonadotrophin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles | 20.0 | 0 | 1 |
| Soft versus firm embryo transfer catheters for assisted reproductive technology | 20.0 | 0 | 1 |
| Cleavage stage versus blastocyst stage embryo transfer in assisted conception | 20.0 | 0 | 1 |
| Ultrasound versus 'clinical touch' for catheter guidance during embryo transfer in women | 20.0 | 0 | 1 |
| Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques | 20.0 | 0 | 1 |
| Post embryo transfer interventions for in vitro fertilization / intracytoplasmic sperm injection patients | 20.0 | 0 | 1 |
| Intrauterine insemination versus fallopian tube sperm perfusion for non tubal infertility | 20.0 | 0 | 1 |
| Luteal phase support in assisted reproduction cycles | 20.0 | 0 | 1 |
| Semen preparation techniques for intrauterine insemination | 20.0 | 0 | 1 |
| Recombinant versus urinary derived gonadotrophins for ovarian stimulation in in vitro fertilisation and intra-cytoplasmic sperm injection cycles | 20.0 | 0 | 1 |
| Day three versus day two embryo transfer following in vitro fertilization or intracytoplasmic sperm injection | 20.0 | 0 | 1 |
| Glucocorticoid supplementation during ovarian stimulation for IVF or ICSI | 20.0 | 0 | 1 |
| Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles | 20.0 | 0 | 1 |
| Single versus double intrauterine insemination (IUI) in stimulated cycles for subfertile couples | 20.0 | 0 | 1 |
| Day 3 versus day 2 embryo transfer following in vitro fertilization or intracytoplasmic sperm injection | 20.0 | 0 | 1 |
| Barriers to patient-physician communication about out-of-pocket costs | 20.0 | 0 | 1 |
| In memoriam: Celso-Ramon Garcia, M.D. (1922-2004), reproductive medicine visionary | 20.0 | 0 | 1 |
| Current achievements and future research directions in ovarian tissue culture, in vitro follicle development and transplantation: implications for fertility preservation | 20.0 | 0 | 1 |
| Frozen-thawed embryo transfer cycles: clinical outcomes of single and double blastocyst transfers | 20.0 | 0 | 1 |
| CardioVascular Care Providers. A pioneer in bundled services, shared risk, and single payment | 20.0 | 0 | 1 |
| Why do patients discontinue fertility treatment? A systematic review of reasons and predictors of discontinuation in fertility treatment | 20.0 | 0 | 1 |
| Relationship of total motile sperm count and percentage motile sperm to successful pregnancy rates following intrauterine insemination | 20.0 | 0 | 1 |
| Different ovarian stimulation protocols for women with diminished ovarian reserve | 20.0 | 0 | 1 |
| Mild ovarian stimulation | 20.0 | 0 | 1 |
| Clomifene citrate or unstimulated intrauterine insemination compared with expectant management for unexplained infertility: pragmatic randomised controlled trial | 20.0 | 0 | 1 |
| Infertility, infertility treatment, and congenital malformations: Danish national birth cohort | 20.0 | 0 | 1 |
| Beckwith-Wiedemann syndrome and assisted reproduction technology (ART) | 20.0 | 0 | 1 |
| Ectopic pregnancy rates with day 3 versus day 5 embryo transfer: a retrospective analysis | 20.0 | 0 | 1 |
| First successful case of in vitro fertilization-embryo transfer with venom immunotherapy for hymenoptera sting allergy | 20.0 | 0 | 1 |
| Genomic imprinting and assisted reproduction | 20.0 | 0 | 1 |
| Monochorionic-triamniotic triplet pregnancy after intracytoplasmic sperm injection, assisted hatching, and two-embryo transfer: first reported case following IVF | 20.0 | 0 | 1 |
| Article processing charges, funding, and open access publishing at Journal of Experimental & Clinical Assisted Reproduction | 20.0 | 0 | 1 |
| Overriding follicle selection in controlled ovarian stimulation protocols: quality vs quantity | 20.0 | 0 | 1 |
| The stork and the syringe: a political history of reproductive medicine | 20.0 | 0 | 1 |
| Low-dose aspirin does not improve ovarian stimulation, endometrial response, or pregnancy rates for in vitro fertilization | 20.0 | 0 | 1 |
| Identification and isolation of embryonic stem cells in reproductive endocrinology: theoretical protocols for conservation of human embryos derived from in vitro fertilization | 20.0 | 0 | 1 |
| Clarifying the role of three-dimensional transvaginal sonography in reproductive medicine: an evidenced-based appraisal | 20.0 | 0 | 1 |
| Housing and Planning Act 1986 | 20.0 | 0 | 1 |
| Money Back Guarantee | 20.0 | 0 | 1 |
| Category:Medicine/Reproductive medicine task force articles needing expert attention | 20.0 | 0 | 1 |
| Cleavage stage versus blastocyst stage embryo transfer in assisted reproductive technology | 20.0 | 0 | 1 |
| Endometrial injury for pregnancy following sexual intercourse or intrauterine insemination | 20.0 | 0 | 1 |
| Cryopreservation of testicular tissue or testicular cell suspensions: a pivotal step in fertility preservation | 20.0 | 0 | 1 |
| Resurgence of Minimal Stimulation In Vitro Fertilization with A Protocol Consisting of Gonadotropin Releasing Hormone-Agonist Trigger and Vitrified-Thawed Embryo Transfer | 20.0 | 0 | 1 |
| Synergies between assisted reproduction technologies and functional genomics | 20.0 | 0 | 1 |
| Fertility preservation in women with cervical, endometrial or ovarian cancers | 20.0 | 0 | 1 |
| Fertility Preservation: A Key Survivorship Issue for Young Women with Cancer | 20.0 | 0 | 1 |
| Models Predicting Success of Infertility Treatment: A Systematic Review | 20.0 | 0 | 1 |
| Risks of spontaneously and IVF-conceived singleton and twin pregnancies differ, requiring reassessment of statistical premises favoring elective single embryo transfer (eSET) | 20.0 | 0 | 1 |
| Surgical treatment for hydrosalpinx prior to in-vitro fertilization embryo transfer: a network meta-analysis | 20.0 | 0 | 1 |
| Fertility treatment in spinal cord injury and other neurologic disease | 20.0 | 0 | 1 |
| Fertility preservation in young patients with cancer | 20.0 | 0 | 1 |
| Fertility Protection in Female Oncology Patients: How Should Patients Be Counseled? | 20.0 | 0 | 1 |
| Non-embryo-destructive Extraction of Pluripotent Embryonic Stem Cells: Implications for Regenerative Medicine and Reproductive Medicine | 20.0 | 0 | 1 |
| Toward precision medicine for preserving fertility in cancer patients: existing and emerging fertility preservation options for women | 20.0 | 0 | 1 |
| Spermatogonial stem cells as a therapeutic alternative for fertility preservation of prepubertal boys | 20.0 | 0 | 1 |
| Fertility preservation for boys and adolescents facing sterilizing medical therapy | 20.0 | 0 | 1 |
| Clinical determinants of mental disorders occurring during the infertility treatment | 20.0 | 0 | 1 |
| Parthenogenesis and Human Assisted Reproduction | 20.0 | 0 | 1 |
| Bibliometric mapping and clustering analysis of Iranian papers on reproductive medicine in Scopus database (2010-2014) | 20.0 | 0 | 1 |
| Sperm selection in natural conception: what can we learn from Mother Nature to improve assisted reproduction outcomes? | 20.0 | 0 | 1 |
| Selective Regulation of Oocyte Meiotic Events Enhances Progress in Fertility Preservation Methods | 20.0 | 0 | 1 |
| Air quality in the assisted reproduction laboratory: a mini-review | 20.0 | 0 | 1 |
| Stem cells in reproductive medicine: ready for the patient? | 20.0 | 0 | 1 |
| The sub-optimal response to controlled ovarian stimulation: manageable or inevitable? | 20.0 | 0 | 1 |
| Surgery for endometriosis-associated infertility: do we exaggerate the magnitude of effect? | 20.0 | 0 | 1 |
| Fertility preservation during cancer treatment: clinical guidelines | 20.0 | 0 | 1 |
| The evaluation of pre and post processing semen analysis parameters at the time of intrauterine insemination in couples diagnosed with male factor infertility and pregnancy rates based on stimulation agent. A retrospective cohort study | 20.0 | 0 | 1 |
| The prognostic profile of subfertile couples and treatment outcome after expectant management, intrauterine insemination and in vitro fertilisation: a study protocol for the meta-analysis of individual patient data | 20.0 | 0 | 1 |
| Fertility Sparing Surgery in Gynecologic Cancer | 20.0 | 0 | 1 |
| The presence, role and clinical use of spermatozoal RNAs | 20.0 | 0 | 1 |
| Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice | 20.0 | 0 | 1 |
| Depression: A shared risk factor for cardiovascular and Alzheimer disease | 20.0 | 0 | 1 |
| Infertility and reproductive medicine clinics of North America | 20.0 | 0 | 1 |
| Iranian journal of reproductive medicine Yazd Research & Clinical Centre for Infertility | 20.0 | 0 | 1 |
| Clinical and experimental reproductive medicine | 20.0 | 0 | 1 |
| Neonatal outcomes among singleton births after blastocyst versus cleavage stage embryo transfer: a systematic review and meta-analysis | 20.0 | 0 | 1 |
| Modern radiation therapy and potential fertility preservation strategies in patients with cervical cancer undergoing chemoradiation | 20.0 | 0 | 1 |
| Levothyroxine treatment and pregnancy outcome in women with subclinical hypothyroidism undergoing assisted reproduction technologies: systematic review and meta-analysis of RCTs | 20.0 | 0 | 1 |
| Reproduction and Breast Cancer Risk | 20.0 | 0 | 1 |
| Double versus single homologous intrauterine insemination for male factor infertility: a systematic review and meta-analysis | 20.0 | 0 | 1 |
| <i>In vitro</i> fertilization in Japan — Early days of <i>in vitro</i> fertilization and embryo transfer and future prospects for assisted reproductive technology — | 20.0 | 0 | 1 |
| Strategies for Fertility Preservation in Young Patients with Cancer: A Comprehensive Approach | 20.0 | 0 | 1 |
| Fertility preservation in young patients′ with cancer | 20.0 | 0 | 1 |
| The longer-term health outcomes for children born as a result of IVF treatment. Part II-Mental health and development outcomes | 20.0 | 0 | 1 |
| Conjoined human oocytes observed during assisted reproduction: description of three cases and review of the literature | 20.0 | 0 | 1 |
| Preservation of ovarian function during chemotherapy and radiotherapy in young women with malignancies | 20.0 | 0 | 1 |
| Efficacy of luteal phase support with vaginal progesterone in intrauterine insemination: a systematic review and meta-analysis | 20.0 | 0 | 1 |
| Mary Barton | 20.0 | 0 | 1 |
| PGS-FISH in reproductive medicine and perspective directions for improvement: a systematic review | 20.0 | 0 | 1 |
| Fertility preservation in cancer women: a multidisciplinary approach | 20.0 | 0 | 1 |
| Journal of in vitro fertilization and embryo transfer : IVF | 20.0 | 0 | 1 |
| Seminars in reproductive endocrinology | 20.0 | 0 | 1 |
| Assisted reproduction reviews | 20.0 | 0 | 1 |
| Annual progress in reproductive medicine | 20.0 | 0 | 1 |
| Journal of experimental & clinical assisted reproduction | 20.0 | 0 | 1 |
| International journal of reproductive medicine | 20.0 | 0 | 1 |
| International journal of gynecological obstetrical and reproductive medicine research | 20.0 | 0 | 1 |
| Journal of fertilization. In vitro IVF worldwide reproductive medicine genetics & stem cell biology | 20.0 | 0 | 1 |
| JBRA assisted reproduction | 20.0 | 0 | 1 |
| Strategies for improving outcome of assisted reproduction in women with polycystic ovary syndrome: systematic review and meta-analysis | 20.0 | 0 | 1 |
| Surgical Aspects of Ovarian Tissue Removal and Ovarian Tissue Transplantation for Fertility Preservation | 20.0 | 0 | 1 |
| Ovarian tissue transport to expand access to fertility preservation: from animals to clinical practice | 20.0 | 0 | 1 |
| Abdominal ectopic pregnancy after in vitro fertilization and single embryo transfer: a case report and systematic review | 20.0 | 0 | 1 |
| Risk of adverse pregnancy and perinatal outcomes after high technology infertility treatment: a comprehensive systematic review | 20.0 | 0 | 1 |
| Are there optimal numbers of oocytes, spermatozoa and embryos in assisted reproduction? | 20.0 | 0 | 1 |
| Methods for endometrial preparation in frozen-thawed embryo transfer cycles | 20.0 | 0 | 1 |
| Vitamin D and assisted reproduction: should vitamin D be routinely screened and repleted prior to ART? A systematic review | 20.0 | 0 | 1 |
| Debating Elective Single Embryo Transfer after in vitro Fertilization: A Plea for a Context-Sensitive Approach | 20.0 | 0 | 1 |
| Granulocyte colony-stimulating factor and reproductive medicine: A review | 20.0 | 0 | 1 |
| Examining the evidence: progesterone supplementation during fresh and frozen embryo transfer | 20.0 | 0 | 1 |
| Induced Pluripotent Stem Cell Potential in Medicine, Specifically Focused on Reproductive Medicine | 20.0 | 0 | 1 |
| Biobanking efforts and new advances in male fertility preservation for rare and endangered species | 20.0 | 0 | 1 |
| Progestins in the Fertility-Sparing Treatment and Retreatment of Patients With Primary and Recurrent Endometrial Cancer | 20.0 | 0 | 1 |
| First do no harm: uterine natural killer (NK) cells in assisted reproduction | 20.0 | 0 | 1 |
| Identifying and Addressing the Needs of Adolescents and Young Adults With Cancer: Summary of an Institute of Medicine Workshop | 20.0 | 0 | 1 |
| Laparoscopic management of ruptured heterotopic pregnancy after intrauterine insemination | 20.0 | 0 | 1 |
| Influence of sexual stimulation on sperm parameters in semen samples collected via masturbation from normozoospermic men or cryptozoospermic men participating in an assisted reproduction programme | 20.0 | 0 | 1 |
| Hysteroscopic cervical canal shaving: a new therapy for cervical stenosis before embryo transfer in patients undergoing in vitro fertilization | 20.0 | 0 | 1 |
| Effectivity of heparin in assisted reproduction | 20.0 | 0 | 1 |
| Recurrent implantation failure in assisted reproduction: how to counsel and manage. B. Treatment options that have not been proven to benefit the couple | 20.0 | 0 | 1 |
| Autoimmune factors in assisted reproduction | 20.0 | 0 | 1 |
| Effects of exogenous LH administration during ovarian stimulation of pituitary down-regulated young oocyte donors on oocyte yield and developmental competence | 20.0 | 0 | 1 |
| Myocardial infarction complicating the initial phase of an ovarian stimulation protocol | 20.0 | 0 | 1 |
| Patient-physician communication about out-of-pocket costs | 20.0 | 0 | 1 |
| Cost-effectiveness modelling of recombinant FSH versus urinary FSH in assisted reproduction techniques in the UK | 20.0 | 0 | 1 |
| Cytoplasmic transfer in assisted reproduction | 20.0 | 0 | 1 |
| Is there a benefit of low-dose aspirin in assisted reproduction? | 20.0 | 0 | 1 |